MicroRNA-29 Compounds, Compositions, and Therapeutic Uses
Patent Information
- Application Number
- JP2023549131
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-10-23
- Filing Date
- 2021-10-25
- Publication Date
- 2024-11-01
AI Technical Summary
Current treatments for diseases involving local collagen dysregulation, such as tendon injuries and tissue fibrosis, are inadequate as they do not effectively address the imbalance in collagen types, particularly the overproduction of collagen 3, leading to biomechanical weakness and chronic damage.
Development of chemically modified microRNA-29 (miR-29) compounds that mimic the activity of native miR-29, specifically targeting collagen 3 expression while maintaining collagen 1 levels, administered locally to directly address collagen dysregulation.
The miR-29 compounds safely and effectively reduce collagen 3 expression, improving tendon healing and structural integrity, offering a single-dose treatment option with minimal systemic distribution and immunogenicity, suitable for conditions like tendinopathy, Peyronie's disease, and Dupuytren's disease.
Smart Images

Figure 00000000_0000_ABST
Abstract
Description
[Technical Field]
[0001] The present invention relates to novel microRNA-29 (miR-29) compounds, compositions containing the same, and their use in therapeutic methods.In particular, the present invention provides miR-29 compounds and compositions that are particularly effective and safe in treating diseases associated with local collagen dysregulation, such as tendon injuries, including tendinopathy, and tissue fibrosis, including Peyronie's disease and Dupuytren's disease.Also provided are advantageous dosages and treatment regimens for miR-29 compounds. Summary of the Invention
[0002] MicroRNAs (miRs) are small non-coding RNAs that act in concert with the RNA-induced silencing complex (RISC) to reduce or prevent translation of messenger RNAs (mRNAs) containing complementary target sequences.
[0003] Members of the miR-29 family have been implicated as post-transcriptional regulators of the extracellular matrix, e.g., collagen. Dysregulation of collagen synthesis, particularly the overproduction of one or more collagen types, contributes to the pathology seen in certain diseases, such as tendon injuries, e.g., tendinopathies, and tissue fibroses, e.g., Peyronie's disease and Dupuytren's disease.
[0004] Previously published studies by the inventors (References 1, 2, 3) established that miR-29 regulates a key disease pathway in collagen production in tendon injury. For example, in healthy tendon cells, miR-29 (e.g., miR-29a, also referred to herein as miR29a) suppresses the overproduction of collagen type 3 (Col3), whereas in tendon disease, there is reduced miR-29 levels and Col3 overproduction, resulting in mechanically deteriorated tendon tissue that is susceptible to further damage. In these studies, the inventors showed that in vitro transfection of tendon cells with miR-29a significantly reduced Col3 expression, while levels of Col1, a desirable, biomechanically superior form of collagen in tendons, remained largely unaffected. The inventors also showed that the majority of Col1 transcripts in tendon cells lacked binding sites for miR-29 due to the use of an alternative polyadenylation site, while the majority of Col3 transcripts in tendon cells retained miR-29 binding sites. Thus, while Col1 transcripts in tendon cells were rendered insensitive to miR-29-mediated downregulation, miR-29 could specifically suppress Col3 in those cells. This was confirmed in an in vivo model of tendon injury, showing that delivery of the miR-29a compound to injured tendons in mice (Refs. 1, 2) or horses (Ref. 3) resulted in a decrease in Col3 synthesis while maintaining Col1 levels. Previous studies have shown that in fibroblasts, miR-29 inhibits the expression of not only Col3 but also other types of collagen, such as Col1 (e.g., Ref. 4).
[0005] The present invention provides improved miR-29 compounds that are particularly effective and safe in therapeutic applications. These compounds are useful in treating any condition requiring increased activity of miR-29 (e.g., miR-29a). This includes conditions involving local collagen dysregulation and requiring reduced or inhibited expression of one or more types of collagen, such as collagen 3, including, but not limited to, tendon injuries, including tendinopathies (e.g., lateral epicondylitis, also known as tennis elbow), and tissue fibroses such as Peyronie's disease and Dupuytren's disease. The compounds described herein mimic the activity of native miR-29, while specific chemical modifications result in improved pharmacological properties, such as increased activity, stability, and cellular uptake, without causing immunogenicity issues. An additional advantage of the compounds and compositions described herein is that they are stable in simple aqueous carriers and can be administered directly to the affected area without the need for reconstitution or dilution.
[0006] Particularly advantageous dosages and treatment regimens of miR-29 compounds for treating diseases such as tendon injuries, including tendinopathy, and tissue fibrosis, such as Peyronie's disease and Dupuytren's disease, are also provided herein. The inventors have shown that administration of miR-29 compounds by local (intratendinous) injection into injured tendons improves tendon healing and tendon fiber quality, for example, in a mouse model of tendinopathy. Surprisingly, therapeutic efficacy can be achieved with only a single administration (i.e., a single dose). Dosages suitable for therapy (e.g., human therapy) are provided. Data supporting the therapeutic efficacy of miR-29 compounds for tissue fibrosis, such as Dupuytren's disease and Peyronie's disease, are also available. miR-29 compounds can be administered locally (intralesionally) at the site of the lesion in a simple aqueous carrier. The data provided herein demonstrate that systemic exposure or distribution to other tissues after local intralesional administration is negligible, thereby providing a particularly safe therapy. Furthermore, because a single administration can be therapeutically effective, only one visit to a medical professional is required, thereby allowing for simple, cost-effective, rapid and effective treatment.
[0007] Disclosure of the Invention In one aspect, the present invention provides miR-29 compounds, compositions containing the same, and their use in therapeutic methods. Accordingly, the present invention provides miR-29 compounds or salts thereof comprising a guide (antisense) strand and a passenger (sense) strand, which mimic the biological activity of native miR-29a, such as downregulating collagen 3 expression. Thus, the compounds of the present invention can reduce or inhibit collagen 3 expression. Because the biological activities of various members of the miR-29 family (miR-29a, miR-29b-1, miR-29b-2, and miR-29c) overlap, the miR-29 compounds provided herein can also mimic the biological activity of other miR-29 family members. Therefore, miR-29 compounds are also referred to as miR-29 mimics or miR-29 mimetic compounds.
[0008] The guide strand and passenger strand of the miR-29 compound are oligonucleotides. That is, they comprise nucleosides linked by internucleoside linkages. The guide strand and passenger strand typically form a duplex containing multiple mismatches and overhangs in at least one strand. The miR-29 compounds described herein are typically chemically modified, meaning that at least one sugar, internucleoside linkage, or nucleobase has a chemical structure different from that in naturally occurring miR-29. The chemical modification(s) can be selected to improve the pharmacological properties of the miR-29 compound, for example, by enhancing its activity and / or stability. Exemplary modified sugars are 2'-fluororibose, 2'-O-methylribose, or 2'-deoxyribose. Exemplary modified internucleoside linkages are phosphorothioate internucleoside linkages. Exemplary modified nucleobases are 5-methylcytosine. The miR-29 compound may be conjugated (i.e., covalently linked) to a lipophilic moiety, such as a cholesterol moiety, typically at the 3' end of the passenger strand. Such conjugation to a lipophilic moiety may improve the properties of the miR-29 compound for in vivo use, for example, by improving its cellular uptake.
[0009] Thus, in one embodiment, the present invention provides a method for treating a cancer cell comprising: (a) a guide strand comprising a nucleobase sequence that differs from 5'-UAGCACCAUCUGAAAUCGGUUA-3' (SEQ ID NO: 1) at no more than five (or no more than four, three, two, or one) positions outside of the sequence 5'-AGCACCA-3' (SEQ ID NO: 8, which is the seed sequence), and optionally at no more than three (or no more than two, or one) positions within the seed sequence, wherein at least one nucleoside comprises 2'-fluororibose and optionally at least one nucleoside comprises 2'-O-methylribose; (b) a passenger strand comprising a nucleobase sequence that differs from 5'-ACUGAUUUCUUUUGGUGUUCAG-3' (SEQ ID NO: 2) at no more than five (or no more than four, three, two, or one, e.g., no more than three) positions, wherein at least one nucleoside comprises 2'-O-methyl ribose and at least one nucleoside comprises an unmodified ribose; The present invention provides a miR-29 compound or a salt thereof comprising:
[0010] A nucleobase sequence "differs" from another nucleobase sequence if there is a different nucleobase, an additional nucleobase, or a missing nucleobase at the corresponding position. A nucleobase sequence that differs from another nucleobase sequence at no more than a certain number of positions also encompasses a nucleobase sequence that differs at zero positions, i.e., the nucleobase sequences may be identical.
[0011] Thus, the nucleobase sequence of the guide strand may differ from the nucleobase sequence of native miR-29a (SEQ ID NO: 1) outside the seed sequence of native miR-29a (AGCACCA, SEQ ID NO: 8) at no more than five positions, for example, at no more than four positions, at no more than three positions, at no more than two positions, or at no more than one position, preferably at no more than three positions. In one embodiment, the nucleobase sequence of the guide strand outside the seed sequence is identical to the corresponding position in SEQ ID NO: 1. Additionally or alternatively, the seed sequence of the guide strand of the miR-29 compound may differ from the seed sequence of native miR-29a (AGCACCA, SEQ ID NO: 8) at no more than three positions, for example, at no more than two positions, or at no more than one position. In a preferred embodiment, the seed sequence is identical to SEQ ID NO: 8.
[0012] The nucleobase sequence of the passenger strand may differ from 5'-ACUGAUUUCUUUUGGUGUUCAG-3' (SEQ ID NO: 2) at no more than five positions, for example no more than four positions. In preferred embodiments, the nucleobase sequence of the passenger strand differs from SEQ ID NO: 2 at no more than three positions. In other embodiments, the nucleobase sequence of the passenger strand differs from SEQ ID NO: 2 at no more than two positions. In particular embodiments, the nucleobase sequence of the passenger strand differs from SEQ ID NO: 2 at no more than one position. This means that the nucleobase sequence of the passenger strand has the sequence of SEQ ID NO: 2 or a sequence that has one different, additional, or missing nucleobase relative to SEQ ID NO: 2. SEQ ID NO: 3 has one missing nucleobase relative to SEQ ID NO: 2.
[0013] Since SEQ ID NO:2 and SEQ ID NO:3 differ at only one position, as noted above, also provided herein are embodiments in which the passenger strand differs from SEQ ID NO:3 at five or fewer positions, etc.
[0014] In one embodiment, the passenger strand is substituted with 5'-ACUGAUUUC at no more than 5 (e.g., 4, 3, 2, or 1 or less, e.g., 3 or less) positions outside the underlined sequences 5'-UUU-3' and / or 5'-UUCA-3 (which correspond to positions 10 to 12 and 18 to 21 of SEQ ID NO: 2) shown above. UUU UGGUG UUCAG-3' (SEQ ID NO: 2). In certain embodiments, the nucleobase sequence of the passenger strand differs from SEQ ID NO: 2 only outside of the sequences 5'-UUU-3' and 5'-UUCA-3'. For example, the nucleobase sequence of the passenger strand may differ from SEQ ID NO: 2 at no more than two positions outside of the sequences 5'-UUU-3' and 5'-UUCA-3'. In certain embodiments, the nucleobase sequence of the passenger strand may differ from SEQ ID NO: 2 at no more than one or two positions, e.g., no more than one position, outside of the sequences 5'-UUU-3' and 5'-UUCA-3'. In certain embodiments, such passenger strands are combined with fluorinated guide strands described herein (e.g., comprising one or more 2'-fluororibonucleosides, e.g., at least 50% of the nucleosides are 2'-fluororibonucleosides, or all nucleosides except one or two 2'-O-methylribose nucleosides, preferably located at the 3' terminus, are 2'-fluororibonucleosides).
[0015] In one embodiment, the guide strand has a nucleobase sequence comprising at least 7 contiguous nucleobases of the nucleobase sequence of SEQ ID NO: 1. For example, the guide strand may have a nucleobase sequence comprising at least 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or at least 21 contiguous nucleobases of the nucleobase sequence of SEQ ID NO: 1. In one embodiment, the guide strand has a nucleobase sequence comprising at least 18 contiguous nucleobases of the nucleobase sequence of SEQ ID NO: 1.
[0016] In the same or other embodiments, the passenger strand may have a nucleobase sequence comprising at least 7 contiguous nucleobases of the nucleobase sequence of SEQ ID NO: 2. For example, the passenger strand may have a nucleobase sequence comprising at least 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or at least 21 contiguous nucleobases of the nucleobase sequence of SEQ ID NO: 2. In one embodiment, the passenger strand has a nucleobase sequence comprising at least 18 contiguous nucleobases of the nucleobase sequence of SEQ ID NO: 2.
[0017] In one embodiment, the guide strand comprises a nucleobase sequence that is at least 85% identical over the entire length of SEQ ID NO: 1. For example, the guide strand may comprise a nucleobase sequence that is at least 90%, 95%, 96%, 97%, 98%, at least 99%, or 100% identical over the entire length of SEQ ID NO: 1. In certain embodiments, the guide strand has a nucleobase sequence as defined above, which comprises the sequence 5'-AGCACCA-3' (SEQ ID NO: 8) at positions corresponding to positions 2-8 of SEQ ID NO: 1. In those embodiments, the nucleobase sequence of the guide strand may differ from SEQ ID NO: 1 only outside positions 2-8 of SEQ ID NO: 1. Differences may be defined by percentage identity or number of identical / different nucleobases, as described above.
[0018] In the same or other embodiments, the passenger strand may comprise a nucleobase sequence that is at least 85% identical over the entire length of SEQ ID NO:2 or 3. For example, the passenger strand may comprise a nucleobase sequence that is at least 90%, 95%, 96%, 97%, 98%, at least 99%, or 100% identical over the entire length of SEQ ID NO:2 or 3. In certain embodiments, the passenger strand has a nucleobase sequence as defined above, which comprises the sequences 5'-UUU3' and / or 5'-UUCA-3' at positions corresponding to positions 10-12 and 18-21 of SEQ ID NO:2. In those embodiments, the nucleobase sequence of the passenger strand may differ from SEQ ID NO:2 only outside of positions 10-12 and / or positions 18-21 of SEQ ID NO:2. In certain embodiments, the nucleobase sequence of the passenger strand may differ from SEQ ID NO:2 only outside of positions 10-12 and 18-21 of SEQ ID NO:2. The difference can be defined as the percentage identity or the number of identical / different nucleobases, as described above. In certain embodiments, such passenger strands are combined with fluorinated guide strands described herein (e.g., comprising one or more 2'-fluororibonucleosides, e.g., at least 50% of the nucleosides are 2'-fluororibonucleosides, or in which all nucleosides except for one or two 2'-O-methylribose nucleosides, preferably located at the 3'-terminus, are 2'-fluororibonucleosides).
[0019] In further embodiments, the guide strand and / or passenger strand may consist of the above-described nucleobase sequences. In certain embodiments, the guide strand comprises or consists of the nucleobase sequence 5'-UAGCACCAUCUGAAAUCGGUUA-3' (SEQ ID NO: 1), and / or the passenger strand comprises or consists of the nucleobase sequence 5'-ACUGAUUUCUUUUGGUGUUCAG-3' (or SEQ ID NO: 2) or 5'-ACUGAUUUCUUUUGGUGUUCA-3' (SEQ ID NO: 3). In certain embodiments, the guide strand comprises or consists of the nucleobase sequence 5'-UAGCACCAUCUGAAAUCGGUUA-3' (SEQ ID NO: 1), and / or the passenger strand comprises or consists of the nucleobase sequence 5'-ACUGAUUUCUUUUGGUGUUCA-3' (SEQ ID NO: 3). In certain embodiments, the guide strand comprises the nucleobase sequence 5'-UAGCACCAUCUGAAAUCGGUUA-3' (SEQ ID NO: 1), and the passenger strand comprises the nucleobase sequence 5'-ACUGAUUUCUUUUGGUGUUCA-3' (SEQ ID NO: 3). In certain embodiments, the guide strand consists of the nucleobase sequence 5'-UAGCACCAUCUGAAAUCGGUUA-3' (SEQ ID NO: 1), and the passenger strand consists of the nucleobase sequence 5'-ACUGAUUUCUUUUGGUGUUCA-3' (SEQ ID NO: 3). In any of these embodiments, the term "consisting of" does not exclude the presence of other (non-nucleoside) moieties attached to the guide strand or passenger strand; for example, the passenger strand may be linked, e.g., via a linker, to a lipophilic moiety, e.g., a cholesterol moiety, typically at the 3' end of the passenger strand.
[0020] In certain embodiments, the nucleobase at the 3'-terminus of the passenger strand is A or G. In certain embodiments, the nucleobase at the 3'-terminus of the passenger strand is A.
[0021] In any of the embodiments described herein, at least or about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or 21 nucleosides of the guide strand can comprise 2'-fluororibose.For example, at least or about 11, 12, 13, 14, 15, 16, 17, 18 or 19 nucleosides of the guide strand are 2'-fluororibose nucleosides.In some embodiments, 20 or less or 21 or less nucleosides of the guide strand are 2'-fluororibose nucleosides.
[0022] In any of the embodiments described herein, at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, or at least 95% of the nucleosides in the guide strand comprise 2'-fluororibose. In some embodiments, at least one nucleoside in the guide strand comprises a sugar other than 2'-fluororibose (which may be a modified sugar). In certain embodiments, at least 50% (or at least 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, or at least 95%) of the nucleosides in the guide strand comprise 2'-fluororibose, and at least one nucleoside in the guide strand comprises 2'-O-methylribose. In another embodiment, at least 50% (or at least 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, or at least 95%) of the nucleosides of the guide strand comprise 2'-fluororibose and at least two nucleosides of the guide strand comprise 2'-O-methylribose. For example, one or two nucleosides of the guide strand can comprise 2'-O-methylribose. The nucleoside of the guide strand that comprises 2'-O-methylribose can be located at the 3' end of the guide strand.
[0023] In one embodiment, at least 50%, 60%, 70%, 80%, or 90% of the nucleosides in the guide strand are 2'-fluororibose nucleosides, and / or no more than 91% or no more than 95% of the nucleosides in the guide strand are 2'-fluororibose nucleosides. For example, at least 50% and no more than 91% of the nucleosides in the guide strand are 2'-fluororibose nucleosides.
[0024] In one embodiment, the nucleosides of the passenger strand that contain 2'-O-methylribose and unmodified ribose are alternately arranged.For example, at least 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or at least 20 consecutive nucleosides in the passenger strand can be alternating 2'-O-methylribose nucleosides and nucleosides with unmodified ribose moieties.Therefore, there can be at least 10 consecutive nucleosides in the passenger strand that are alternating 2'-O-methylribose nucleosides and nucleosides with unmodified ribose moieties.There can be at least 12 consecutive nucleosides in the passenger strand that are alternating 2'-O-methylribose nucleosides and nucleosides with unmodified ribose moieties. There may be at least 14 consecutive nucleosides in the passenger strand that are alternating 2'-O-methylribose nucleosides and nucleosides with unmodified ribose moieties. There may be at least 16 consecutive nucleosides in the passenger strand that are alternating 2'-O-methylribose nucleosides and nucleosides with unmodified ribose moieties. In a preferred embodiment, there may be at least 18 consecutive nucleosides in the passenger strand that are alternating 2'-O-methylribose nucleosides and nucleosides with unmodified ribose moieties. One or more nucleosides in the passenger strand may contain deoxyribose. Such nucleosides may be located at the 3' end of the passenger strand.
[0025] In one embodiment, at least 5, 6, 7, 8, or 9 nucleosides of the passenger strand are 2'-O-methyl ribose nucleosides and / or no more than 10 nucleosides of the passenger strand are 2'-O-methyl ribose nucleosides.
[0026] In one embodiment, at least 10%, 20%, 30%, 40% or 45% of the nucleosides of the passenger strand are 2'-O-methyl ribose nucleotides and / or no more than 50% of the oligonucleotides of the passenger strand are 2'-O-methyl ribose nucleotides.
[0027] Thus, the present invention provides a miR-29 compound, or a salt thereof, comprising a guide strand as described in any of the embodiments herein and a passenger strand as described in any of the embodiments herein.
[0028] Thus, in one embodiment, the present invention provides a method for treating a cancer cell comprising: (a) a guide strand comprising a nucleobase sequence that differs from SEQ ID NO: 1 at no more than five positions outside the nucleobase sequence 5'-UAGCACCAUCUGAAAUCGGUUA-3' (SEQ ID NO: 1) or the sequence 5'-AGCACCA-3' (SEQ ID NO: 8), and optionally at no more than three positions within the sequence, wherein at least 50% of the nucleosides comprise 2'-fluororibose and one or two nucleosides, preferably at the 3' terminus, each comprise 2'-O-methylribose; (b) a passenger strand comprising the nucleobase sequence 5'-ACUGAUUUCUUUUGGUGUUCAG-3' (SEQ ID NO: 2) or 5'-ACUGAUUUCUUUUGGUGUUCA-3' (SEQ ID NO: 3), or a nucleobase sequence that differs from SEQ ID NO: 2 at no more than three positions, wherein at least 10 consecutive nucleosides are alternating 2'-O-methyl ribose nucleosides and nucleosides having an unmodified ribose moiety; The present invention provides a miR-29 compound or a salt thereof comprising:
[0029] In certain embodiments, the present invention provides a method for producing a pharmaceutical composition comprising: (a) a guide strand comprising a nucleobase sequence that differs from SEQ ID NO: 1 at no more than three positions outside the nucleobase sequence 5'-UAGCACCAUCUGAAAUCGGUUA-3' or the sequence 5'-AGCACCA-3' (SEQ ID NO: 8), wherein at least 50% of the nucleosides comprise 2' fluororibose and one or two nucleosides at the 3' terminus each comprise 2'-O-methylribose; (b) a passenger strand comprising the nucleobase sequence 5'-ACUGAUUUCUUUUGGUGUUCAG-3' (SEQ ID NO: 2) or 5'-ACUGAUUUCUUUUGGUGUUCA-3' (SEQ ID NO: 3), or a nucleobase sequence that differs from SEQ ID NO: 2 at no more than three positions, wherein at least 10 consecutive nucleosides are alternating 2'-O-methyl ribose nucleosides and nucleosides having an unmodified ribose moiety; The present invention provides a miR-29 compound or a salt thereof comprising:
[0030] Exemplary compounds according to this embodiment are Teno15, Teno18, Teno19, Teno20, Teno29, Teno32, Teno33 and Teno34, which are described in the Examples below.
[0031] As described above, at least 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or at least 20 consecutive nucleosides in the passenger strand can be alternating 2'-O-methylribose nucleosides and nucleosides having unmodified ribose moieties. For example, at least 12 consecutive nucleosides in the passenger strand are alternating 2'-O-methylribose nucleosides and nucleosides having unmodified ribose moieties. For example, at least 14 consecutive nucleosides in the passenger strand are alternating 2'-O-methylribose nucleosides and nucleosides having unmodified ribose moieties. For example, at least 16 consecutive nucleosides in the passenger strand are alternating 2'-O-methylribose nucleosides and nucleosides having unmodified ribose moieties. In certain embodiments, for example, at least 18 consecutive nucleosides in the passenger strand are alternating 2'-O-methyl ribose nucleosides and nucleosides having unmodified ribose moieties.
[0032] Preferably, at least one or two nucleosides in the passenger strand each containing a 2'-O methyl ribose are located at the 3' end of the passenger strand, although this is not required.
[0033] In certain embodiments, one or two nucleosides at the 3' end of the guide strand may each contain 2'-O-methyl ribose, and: (i) each of the remaining nucleosides in the guide strand that contain a 2'-modified ribose is a 2'-fluoro ribose nucleoside, or (ii) each of the remaining nucleosides in the guide strand is a 2'-fluoro ribose nucleoside or an unmodified ribose moiety.
[0034] In certain embodiments, (i) each nucleoside of the guide strand comprises a 2'-modified ribose, (ii) each nucleoside of the guide strand comprises a 2'-O-methyl ribose or a 2'-fluoro ribose, or (iii) one or two nucleosides at the 3' end of the guide strand each comprise a 2'-O-methyl ribose, and the remaining nucleosides of the guide strand are each 2'-fluoro ribose nucleosides.
[0035] In some embodiments, none of the internucleoside linkages of the guide strand and / or passenger strand are chemically modified. Thus, in some embodiments, all of the internucleoside linkages of the guide strand and / or passenger strand are phosphodiester internucleoside linkages.
[0036] In some embodiments, none of the nucleobases of the guide strand and / or passenger strand are chemically modified, e.g., in some embodiments, none of the nucleobases of the guide strand and / or passenger strand comprise 5-methylcytosine.
[0037] In certain embodiments, the nucleobase sequence of the guide strand is as defined in SEQ ID NO:1 and / or the nucleobase sequence of the passenger strand is as defined in SEQ ID NO:2 or SEQ ID NO:3.
[0038] In an embodiment, the nucleobase sequence of the guide strand is as defined in SEQ ID NO:1 and / or the nucleobase sequence of the passenger strand is as defined in SEQ ID NO:3.
[0039] In one embodiment, the guide strand is 5'-fUfAfGfCfAfCfAfUfCfUfGfAfAfAfUfCfGfGfUmUmA-3'; the passenger is 5'-mArCmUrGmArUmUrUmCrUmUrUmUrGmGrUmGrUmUrCdA-3'; where "f" preceding the nucleoside = 2'-deoxy-fluororibonucleoside (-F); "m" preceding the nucleoside = 2'-O-methylribonucleoside (-O-Me); "r" preceding the nucleoside = nucleoside having an unmodified ribose moiety (OH); and "d" preceding the nucleoside = 2'-deoxyribonucleoside (-H). An exemplary compound according to this embodiment is Tenol8, which is illustrated in the Examples below.
[0040] In certain embodiments, the guide strand is 5'-fUfAfGfCfAfCfAfUfCfUfGfAfAfAfUfCfGfGfUmUmA-3'; the passenger is 5'-mAmCrUmGrAmUrUmUrCmUrUmUrUmGrGmUrGmUrUmCmAmG-3'; where "f" preceding the nucleoside = 2'-deoxy-fluororibonucleoside (-F); "m" preceding the nucleoside = 2'-O-methylribonucleoside (-O-Me); and "r" preceding the nucleoside = a nucleoside having an unmodified ribose moiety (OH). An exemplary compound according to this embodiment is Teno 20, as described in the Examples below.
[0041] In certain embodiments, the guide strand is 5'-fUrArGfCrAfCfCrAfUfCfUrGrArArAfUfCrGrGfUfUmA-3; the passenger is 5'-mArCmUrGmArUmUrUmCrUmUrUmUrGmGrUmGrUmUrCmAdG-3'; where "f" preceding the nucleoside = 2'-deoxy-fluororibonucleoside (-F); "m" preceding the nucleoside = 2'-O-methylribonucleoside (-O-Me); "r" preceding the nucleoside = nucleoside having an unmodified ribose moiety (OH); and "d" preceding the nucleoside = 2'-deoxyribonucleoside (-H). An exemplary compound according to this embodiment is Teno33, as described in the Examples below.
[0042] In any of the embodiments described herein, the miR-29 compound or its salt may further comprise a cholesterol moiety covalently attached to the 3'-end of the passenger strand. The cholesterol moiety may be a triethylene glycol cholesterol moiety. An exemplary cholesterol moiety is 3'phosphopropyl-2-ol,2,2'-[ethane-1,2-diylbis(oxy)]di(ethan-1-ol),10-O-[1-propyl-3-N-carbamoylcholesteryl].
[0043] In an exemplary embodiment, the guide strand is 5'-fUfAfGfCfAfCfAfUfCfUfGfAfAfAfUfCfGfGfUmUmA-3'; the passenger is 5'-mArCmUrGmArUmUrUmCrUmUrUmUrGmGrUmGrUmUrCdAchol-3; "f" preceding the nucleoside = 2'-deoxy-fluororibonucleoside (-F); "m" preceding the nucleoside = 2'-O-methylribonucleoside (-O-Me); "r" preceding the nucleoside = nucleoside having an unmodified ribose moiety (OH); "d" preceding the nucleoside = 2'-deoxyribonucleoside (-H); and chol denotes a cholesterol moiety. An exemplary compound according to this embodiment is the cholesterol conjugate Tenol8 (CWT-001), which is illustrated in the Examples below.
[0044] In any of these embodiments, the 5'-terminal nucleoside of the guide strand may have a phosphate group at the 5'-position of the sugar ("5'Phos").
[0045] Thus, in one embodiment, the guide strand is 5'-PhosfUfAfGfCfAfCfAfUfCfUfGfAfAfAfUfCfGfGfUmUmA-3'; and the passenger strand is 5'-mArCmUrGmArUmUrUmCrUmUrUmUrGmGrUmGrUmUrCdA-3; wherein all internucleoside linkages of the guide strand and passenger strand are phosphodiester internucleoside linkages. An exemplary compound according to this embodiment is Tenol8, as illustrated in the Examples below.
[0046] In another embodiment, the guide strand is 5'-PhosfUfAfGfCfAfCfAfUfCfUfGfAfAfAfUfCfGfGfUmUmA-3'; the passenger strand is 5'-mArCmUrGmArUmUrUmCrUmUrUmUrGmGrUmGrUmUrCdAchol-3; where chol is a cholesterol moiety, e.g., a triethylene glycol cholesterol moiety, and all internucleoside linkages of the guide strand and passenger strand are phosphodiester internucleoside linkages. An exemplary compound according to this embodiment is the cholesterol conjugate Tenol8 (CWT-001), which is illustrated in the Examples below.
[0047] The present invention also provides pharmaceutical compositions comprising the miR-29 compounds or salts thereof described herein. Pharmaceutical compositions typically include a pharmaceutically acceptable carrier or diluent. In certain embodiments, the pharmaceutically acceptable carrier or diluent is a sterile solution. The pharmaceutically acceptable carrier or diluent is a parenterally acceptable aqueous solution. For example, the pharmaceutically acceptable carrier or diluent may be phosphate-buffered saline (PBS). The pharmaceutically acceptable carrier or diluent may contain an additional substance, such as EDTA, at a final concentration of, for example, 0.001% to 0.005%, e.g., 0.003% (100 μM). In certain embodiments, the pharmaceutical composition does not include a non-liquid carrier; for example, the miR-29 compound or salt thereof is not contained in, administered to, or administered with a solid carrier, such as an implantable scaffold.
[0048] The present invention further provides a container containing a miR-29 compound or a salt thereof described herein. The miR-29 compound or a salt thereof is typically provided in a therapeutically effective amount. A therapeutically effective amount is the amount of the miR-29 compound or a salt thereof that, when administered to a subject, reduces or inhibits collagen 3 and typically results in an improvement in disease symptoms, e.g., relief from pain or disability, improved functionality, and / or delayed disease progression. The container typically includes a label affixed to the container. The container may be a glass vial (e.g., a disposable glass vial) containing the pharmaceutical composition described herein. The container may also be a syringe or injector.
[0049] The present invention also provides a miR-29 compound or a salt thereof, or a pharmaceutical composition described herein for use in therapy.
[0050] Accordingly, also provided herein is the use of a miR-29 compound or a salt thereof, or a pharmaceutical composition described herein, for the manufacture of a medicament.
[0051] Also provided are methods for treating a disease or condition, comprising administering to a subject in need thereof a therapeutically effective amount of a miR-29 compound or a salt thereof, or a pharmaceutical composition described herein.
[0052] Terms such as "therapy," "medication," "treat," and "treatment" include curative and prophylactic methods.
[0053] Thus, in a preferred embodiment, provided herein is a miR-29 compound or a salt thereof for use in therapy, including, for example, intralesional administration by injection (e.g., a single intralesional administration) of the miR-29 compound or salt thereof, wherein the miR-29 compound or salt thereof comprises a guide strand 5'-fUfAfGfCfAfCfCfAfUfCfUfGfAfAfAfUfCfGfGfUmUmA-3' and a passenger strand 5'-mArCmUrGmArUmUrUmCrUmUrUmUrGmGrUmGrUmUrCdA-3', optionally wherein a lipophilic (e.g., cholesterol) moiety is covalently attached to the 3' end of the passenger strand.
[0054] In certain embodiments, the treatment is for collagen dysregulation, particularly collagen overproduction, e.g., overproduction of collagen 3. The term "overproduction" refers to increased collagen production compared to corresponding healthy tissue. The overproduction is typically localized. For example, tendon injuries, such as tendinopathy, involve localized overproduction of collagen 3. Fibrotic conditions, such as Peyronie's disease and Dupuytren's disease, also involve localized overproduction of collagen 3. Thus, in one embodiment, the miR-29 compound or salt thereof, or pharmaceutical composition described herein is for use in treating tendon injuries, such as tendinopathy, or tissue fibrosis, such as Peyronie's disease or Dupuytren's disease. In one embodiment, the miR-29 compound or salt thereof, or pharmaceutical composition described herein is for use in treating tendon injuries. The tendon injury can be tendinopathy. The tendon injury can be chronic tendinopathy. The tendon injury can be lateral epicondylitis.
[0055] The subject is typically a human, but another preferred subject is a horse, particularly a sport horse.
[0056] In another aspect, the present invention provides dosages and treatment regimens for miR-29 compounds, their salts, and pharmaceutical compositions containing them.The dosages and treatment regimens provided herein are suitable for a range of miR-29 compounds.That is, the applicability of the dosages and treatment regimens disclosed herein includes, but is not limited to, the novel miR-29 compounds provided herein.Nevertheless, the inventors have found that these dosages and treatment regimens are particularly suitable for these compounds, and therefore these dosages and treatment regimens preferably include novel miR-29 compounds.
[0057] The miR-29 compounds for use in the dosages and treatment regimens disclosed herein may be chemically modified, as described above. This means that at least one sugar, internucleoside linkage, or nucleobase has a chemical structure different from that of naturally occurring miR-29, as also described above. In certain embodiments, the miR-29 compound or its salt contains a modified sugar but does not contain a modified internucleoside linkage or modified nucleobase (the miR-29 compound or its salt does not contain a modified internucleoside linkage, and it does not contain a modified nucleobase). For example, all of the internucleoside linkages of the guide strand and / or passenger strand may be phosphodiester internucleoside linkages. The miR-29 compound may be conjugated (i.e., covalently linked) to a lipophilic moiety, such as a cholesterol moiety, typically at the 3' end of the passenger strand. The miR-29 compound or its salt may be any one of the specific compounds or salts described herein, or it may be a different miR-29 compound or salt thereof.
[0058] Thus, in one embodiment of this aspect, the present invention provides a miR-29 compound or a salt thereof for use in a therapy comprising a single intralesional injection of a dose of the miR-29 compound or a salt thereof. Corresponding uses for the manufacture of medicaments and corresponding methods of treatment are also provided, as described above and below.
[0059] In certain embodiments, the treatment comprises no more than two, or no more than three, intralesional injections of the miR-29 compound or salt thereof, hi other embodiments, the treatment comprises a single intralesional injection of the miR-29 compound or salt thereof.
[0060] The treatment may be for tendon injury (eg, tendinopathy), with administration occurring in the damaged area of the tendon (intra-tendon or intratendinous).
[0061] The treatment can be for Peyronie's disease, and administration is into the affected area of the subject's tunica albuginea.
[0062] The treatment can be for Dupuytren's disease, and administration is into the affected area of the palmar fascia of the subject.
[0063] In any of these embodiments, a single dose of the miR-29 compound can be 10 μg to 5000 μg of the miR-29 compound, or an equivalent dose of a salt thereof. As explained in more detail below, unless otherwise specified, doses refer to the weight of the oligonucleotide portions of the guide and passenger strands as free acids (i.e., excluding any conjugate groups, such as cholesterol moieties).
[0064] Thus, a single dose can be 10 μg to 4500 μg, 10 μg to 4000 μg, 10 μg to 3500 μg, 10 μg to 3000 μg, or 10 μg to 2500 μg of a miR-29 compound, or an equivalent dose of a salt thereof.
[0065] A single dose can be 47 μg to 4740 μg of the miR-29 compound, or an equivalent dose of a salt thereof. A single dose can be 47 μg to 4270 μg of the miR-29 compound, or an equivalent dose of a salt thereof. A single dose can be 47 μg to 1900 μg of the miR-29 compound, or an equivalent dose of a salt thereof. A single dose can be 47 μg to 1420 μg of the miR-29 compound, or an equivalent dose of a salt thereof. A single dose can be 47 μg to 475 μg of the miR-29 compound, or an equivalent dose of a salt thereof.
[0066] A single dose can be 95 μg to 4740 μg of the miR-29 compound, or an equivalent dose of a salt thereof. A single dose can be 95 μg to 4270 μg of the miR-29 compound, or an equivalent dose of a salt thereof. A single dose can be 95 μg to 1900 μg of the miR-29 compound, or an equivalent dose of a salt thereof. A single dose can be 95 μg to 1420 μg of the miR-29 compound, or an equivalent dose of a salt thereof. A single dose can be 95 μg to 475 μg of the miR-29 compound, or an equivalent dose of a salt thereof.
[0067] A single dose can be 190 μg to 4740 μg of the miR-29 compound, or an equivalent dose of a salt thereof. A single dose can be 190 μg to 4270 μg of the miR-29 compound, or an equivalent dose of a salt thereof. A single dose can be 190 μg to 1900 μg of the miR-29 compound, or an equivalent dose of a salt thereof. A single dose can be 190 μg to 1420 μg of the miR-29 compound, or an equivalent dose of a salt thereof. A single dose can be 190 μg to 475 μg of the miR-29 compound, or an equivalent dose of a salt thereof.
[0068] A single dose can be 475 μg to 4740 μg of the miR-29 compound, or an equivalent dose of a salt thereof. A single dose can be 475 μg to 4270 μg of the miR-29 compound, or an equivalent dose of a salt thereof. A single dose can be 475 μg to 1900 μg of the miR-29 compound, or an equivalent dose of a salt thereof. A single dose can be 475 μg to 1420 μg of the miR-29 compound, or an equivalent dose of a salt thereof.
[0069] A single dose can be 1420 μg to 4740 μg of the miR-29 compound, or an equivalent dose of a salt thereof. A single dose can be 1420 μg to 4270 μg of the miR-29 compound, or an equivalent dose of a salt thereof. A single dose can be 1420 μg to 1900 μg of the miR-29 compound, or an equivalent dose of a salt thereof.
[0070] In some embodiments, a single dose is 190 μg to 1420 μg of a miR-29 compound, or an equivalent dose of a salt thereof. A single dose can be about 190 μg, 475 μg, 1420 μg, or 4270 μg of a miR-29 compound, or an equivalent dose of a salt thereof. For example, a single dose can be about 190 μg, 475 μg, or 1420 μg of a miR-29 compound, or an equivalent dose of a salt thereof. This means that a single dose can be about 190 μg of a miR-29 compound, or an equivalent dose of a salt thereof. A single dose can be about 475 μg of a miR-29 compound, or an equivalent dose of a salt thereof. A single dose can be about 1420 μg of a miR-29 compound, or an equivalent dose of a salt thereof.
[0071] In a preferred embodiment, a single dose is about 190 μg to about 475 μg of a miR-29 compound, or an equivalent dose of a salt thereof. For example, a single dose can be about 190 μg of a miR-29 compound, or an equivalent dose of a salt thereof. Alternatively, a single dose can be about 475 μg of a miR-29 compound, or an equivalent dose of a salt thereof. In a preferred embodiment, a single dose is about 190 μg of a miR-29 compound, or an equivalent dose of a salt thereof.
[0072] In one embodiment, the present invention therefore provides a miR-29 compound or a salt thereof for use in treating a tendon injury in a subject, the treatment comprising a single administration by injection of a dose of at least 47 μg of the miR-29 compound, or an equivalent dose of a salt thereof, into the injured tendon of the subject.
[0073] In another embodiment, the present invention provides a miR-29 compound or a salt thereof for use in treating Peyronie's disease in a subject, the treatment comprising a single injection of at least a 47 μg dose of the miR-29 compound, or an equivalent dose of a salt thereof, into the affected area of the tunica albuginea of the subject.
[0074] In a further embodiment, the present invention provides a miR-29 compound or a salt thereof for use in treating Dupuytren's disease in a subject, the treatment comprising a single injection of at least a 47 μg dose of a miR-29 compound, or an equivalent dose of a salt thereof, into the affected area of the palmar fascia of the subject.
[0075] In certain embodiments, a single dose of the miR-29 compound is at least 95 μg, at least 190 μg, at least 475 μg, at least 1420 μg, at least 1900 μg, at least 4270 μg, or an equivalent dose of a salt thereof.
[0076] For example, a single dose of a miR-29 compound can be at least 95 μg (or at least 190 μg, at least 475 μg, at least 1420 μg, at least 1900 μg, at least 4270 μg) of a miR-29 compound and up to 4740 μg or an equivalent dose of a salt thereof. Thus, a single dose can be within a particular range as described above.
[0077] More typically, a single dose of a miR-29 compound comprises at least about 10 μg, 15 μg, 20 μg, 25 μg, 30 μg, 35 μg, 40 μg, 45 μg, 47 μg, 50 μg, 55 μg, 60 μg, 75 μg, 80 μg, 95 μg, 100 μg, 110 μg, 120 μg, 130 μg, 140 μg, 150 μg, 160 μg, 170 μg, 180 μg, 190 μg, 200 μg, 220 μg, 240 μg, 260 μg, 280 μg, 300 μg, 320 μg, 340 μg, 360 μg, 370 μg, 380 μg, 390 μg, 400 μg, 410 μg, 420 μg, 430 μg, 440 μg, 450 μg, 460 μg, 470 μg, 480 μg, 490 μg, 500 μg, 510 μg, 520 μg, 530 μg, 540 μg, 550 μg, 560 μg, 570 μg, 580 μg, 590 μg, 600 μg, 610 μg, 620 μg, 630 μg, 640 μg, 650 μg, 660 μg, 670 μg, 680 μg, 690 μg, 700 μg, 710 μg, 720 μg, 730 μg, 740 μg, 750 The dosage may be 350 μg, 360 μg, 380 μg, 400 μg, 420 μg, 440 μg, 460 μg, 470 μg, 475 μg, 480 μg, 500 μg, 550 μg, 600 μg, 650 μg, 700 μg, 750 μg, 800 μg, 850 μg, 900 μg, 950 μg, 1000 μg, 1100 μg, 1200 μg, 1300 μg, 1400 μg, 1420 μg, 1500 μg, 1600 μg, 1700 μg, 1800 μg, 1900 μg, or 2000 μg, or an equivalent dose of a salt thereof. In some embodiments, a higher dosage of 4000 μg to 4500 μg, such as 4270 μg, may be used.
[0078] In certain embodiments, which may be combined with other embodiments described herein, a single dose of a miR-29 compound is 190 μg or less, 200 μg, 220 μg, 240 μg, 260 μg, 280 μg, 300 μg, 320 μg, 340 μg, 350 μg, 360 μg, 380 μg, 400 μg, 420 μg, 440 μg, 460 μg, 470 μg, 475 μg, 480 μg, 500 μg, 550 μg, 600 μg, 650 μg, 700 μg, 750 μg, 800 μg, 850 μg, 90 μg, 100 μg, 110 μg, 120 μg, 130 μg, 140 μg, 150 μg, 160 μg, 170 μg, 180 μg, 190 μg, 200 μg, 220 μg, 240 μg, 260 μg, 280 μg, 300 μg, 320 μg, 340 μg, 350 μg, 360 μg, 380 μg, 400 μg, 420 μg, 440 μg, 460 μg, 470 μg, 475 μg, 480 μg, 500 μg, 550 μg, 600 μg, 650 μg, 700 μg, 750 μg, 800 μg, 850 μg, 90 μg, 100 μg, 110 μg, 120 μg, 130 μg, 1 0 μg, 950 μg, 1000 μg, 1100 μg, 1200 μg, 1300 μg, 1400 μg, 1420 μg, 1500 μg, 1600 μg, 1700 μg, 1800 μg, 1900 μg, 2000 μg, 2200 μg, 2400 μg, 2600 μg, 2800 μg, 3000 μg, 3200 μg, 3400 μg, 3600 μg, 3800 μg, 4000 μg, 4200 μg, 4270 μg, 4400 μg, 4600 μg, 4740 μg, 4800 μg or 5000 μg, or an equivalent dose of a salt thereof. In certain embodiments, a single dose of the miR-29 compound is 190 μg or less, or an equivalent dose of its salt. In certain embodiments, a single dose of the miR-29 compound is 475 μg or less, or an equivalent dose of its salt. In certain embodiments, a single dose of the miR-29 compound is 1420 μg or less, or an equivalent dose of its salt. In certain embodiments, a single dose of the miR-29 compound is 1900 μg or less, or an equivalent dose of its salt. In certain embodiments, a single dose of the miR-29 compound is 4270 μg or less, or an equivalent dose of its salt.
[0079] When tendon injuries are treated, the tendon injury may be tendinopathy. The tendon injury may be chronic tendinopathy. The tendon injury may be lateral epicondylitis, medial epicondylitis, rotator cuff tendinopathy, common extensor origin tendinopathy, common flexor origin tendinopathy, gluteal tendinopathy (greater trochanteric pain syndrome, GTPS), patellar tendinopathy, jumper's knee, plantar fasciitis, Achilles tendinopathy, peroneal tendinopathy, supraspinatus syndrome, or a combination thereof. In one embodiment, the tendon injury is an upper limb tendinopathy (such as lateral epicondylitis, golfer's elbow, rotator cuff tendinopathy, and De Quervain's disease). In a specific embodiment, the tendon injury is lateral epicondylitis.
[0080] The subject is typically a human, but another preferred subject is a horse, particularly a sport horse.
[0081] In certain embodiments, the miR-29 compound or a salt thereof is administered in a volume of 0.5 ml to 5 ml, for example, 0.5 ml to 1.5 ml, for example, 0.8 ml to 1.2 ml, for example, 0.9 ml to 1.1 ml. For example, the volume can be about 0.5 ml, 0.75 ml, 1 ml, 1.25 ml, 1.5 ml, 1.75 ml, 2 ml, 2.5 ml, 3 ml, 3.5 ml, 4 ml, 4.5 ml, or about 5 ml. In certain embodiments, the volume is about 1 ml. For example, in one embodiment, the miR-29 compound or a salt thereof is administered in a volume of about 1 ml of sterile aqueous solution.
[0082] The miR-29 compound or its salt can be administered at a concentration corresponding to any of the above dosages. For example, if the dosage is 190 μg of the miR-29 compound, the compound can be administered at a concentration of 190 μg / ml.
[0083] In certain embodiments, the miR-29 compound or salt thereof is any one of the specific miR-29 compounds or salts thereof provided herein.
[0084] Thus, in certain embodiments, the present invention provides a miR-29 compound or a salt thereof for use in a therapy comprising a single intralesional administration by injection of a dose of a miR-29 compound or a salt thereof, wherein the guide strand is a 5' -fUfAfGfCfAfCfAfUfCfUfGfAfAfAfUfCfGfGfUmUmA-3', and the passenger strand is 5'-mArCmUrGmArUmUrUmCrUmUrUmUrGmGrUmGrUmUrCdA-3', and comprises a cholesterol moiety covalently attached to the 3' end of the passenger strand (5'-mArCmUrGmArUmUrUmCrUmUrUmUrGmGrUmGrUmUrCdAchol-3'), and the dose of the miR-29 compound (including the weight of the cholesterol moiety) is 50 μg to 5000 μg, for example, 200 μg to 4500 μg, for example, 200 μg to 1500 μg, 00 μg to 500 μg, 500 μg to 1500 μg, or 1500 μg to 4500 μg (e.g., about 100 μg, 200 μg, 250 μg, 300 μg, 500 μg, 1000 μg, 1500 μg, or about 4500 μg), or an equivalent dose of a salt thereof; where "f" preceding the nucleoside = 2'-deoxy-fluororibonucleoside (-F); "m" preceding the nucleoside = 2'-O-methylribonucleoside (-O-Me); "r" preceding the nucleoside = nucleoside having an unmodified ribose moiety (-OH); and "d" preceding the nucleoside = 2'-deoxyribonucleoside (-H). In a preferred embodiment, the dose of the miR-29 compound (including the weight of the cholesterol moiety) is about 200 μg to about 500 μg, or an equivalent dose of a salt thereof. For example, the dose of the miR-29 compound (including the weight of the cholesterol moiety) can be about 200 μg, or an equivalent dose of a salt thereof. Alternatively, the dose of the miR-29 compound (including the weight of the cholesterol moiety) can be about 500 μg, or an equivalent dose of a salt thereof. In a specific embodiment, the dose of the miR-29 compound (including the weight of the cholesterol moiety) is about 200 μg, or an equivalent dose of a salt thereof.
[0085] Thus, in one embodiment, the guide strand of the miR-29 compound or its salt is 5'-fUfAfGfCfAfCfAfUfCfUfGfAfAfAfUfCfGfGfUmUmA-3', the passenger strand of the miR-29 compound or its salt is 5'-mArCmUrGmArUmUrUmCrUmUrUmUrGmGrUmGrUmUrCdA-3', and comprises a cholesterol moiety covalently attached to the 3' end of the passenger strand, and the dose of the miR-29 compound, including the weight of the cholesterol moiety, is 50 μg to 5000 μg, for example, 200 μg, 500 μg, 1500 μg, or 4500 μg, or an equivalent dose of a salt thereof. This means that the dose of the miR-29 compound, including the weight of the cholesterol moiety, can be about 200 μg, or an equivalent dose of a salt thereof. The dose of the miR-29 compound, including the weight of the cholesterol moiety, may be about 500 μg, or an equivalent dose of its salt. The dose of the miR-29 compound, including the weight of the cholesterol moiety, may be about 1500 μg, or an equivalent dose of its salt. The dose of the miR-29 compound, including the weight of the cholesterol moiety, may be about 4500 μg, or an equivalent dose of its salt. In a preferred embodiment, the dose of the miR-29 compound (including the weight of the cholesterol moiety) is about 200 μg to about 500 μg, or an equivalent dose of its salt. For example, the dose of the miR-29 compound (including the weight of the cholesterol moiety) may be about 200 μg, or an equivalent dose of its salt. The dose of the miR-29 compound (including the weight of the cholesterol moiety) may be about 500 μg, or an equivalent dose of its salt. In a specific embodiment, the dose of the miR-29 compound (including the weight of the cholesterol moiety) is about 200 μg, or an equivalent dose of its salt. The treatment can be for tissue fibrosis, such as Peyronie's disease or Dupuytren's disease. The treatment can be for tendon injury. The tendon injury can be tendinopathy. The tendon injury can be chronic tendinopathy. The tendon injury can be lateral epicondylitis. The miR-29 compound can be administered as a salt, for example, as a sodium salt. The carrier can be a parenterally acceptable sterile aqueous solution, for example, PBS.
[0086] In another aspect, the present invention provides a process for making an miR-29 compound according to the present invention. The present invention also provides a process for making a pharmaceutical composition, comprising providing an miR-29 compound according to the present invention and mixing the compound with a pharmaceutically acceptable carrier or diluent.
[0087] MicroRNA-29 Compounds As used herein, "microRNA-29" compounds refer to oligonucleotides that possess the biological function of natural, endogenous miR-29, including miR-29a, miR-29b (including miR-29b-1 and miR-29b-2), and miR-29c. Their function involves targeting any target mRNA that contains one or more binding sites for miR-29 (e.g., one or more binding sites for miR-29a) by complementary binding (hybridizing) to the 3' untranslated region (3'UTR) of the mRNA, thereby causing its degradation and / or translational repression. Target mRNAs that retain binding sites for miR-29 typically encode specific extracellular matrix proteins, such as collagen, e.g., collagen 3 (col3a1). The miR-29 compounds described herein mimic the biological function of native miR-29, but may be modified relative to native miR-29 (e.g., native miR-29a) to, for example, enhance its activity, stability, and / or cellular uptake, but without causing immunogenicity. Modifications may include modifications of the nucleobase sequence and / or chemical modifications in one or more sugar moieties, internucleoside linkages, and / or nucleobases. Modifications may also include, for example, conjugation to a lipophilic moiety. In one embodiment, the compound has the biological function of human mature miR-29a, i.e., it is a mimic of human mature miR-29a.
[0088] The miR-29 compounds described herein can reduce or inhibit the expression of proteins encoded by mRNAs bearing one or more binding sites for miR-29, e.g., one or more binding sites for miR-29a. For example, the miR-29 compounds described herein can reduce or inhibit collagen expression, e.g., collagen 3 (col3a1). The miR-29 compounds can reduce collagen expression to a greater extent than native miR-29a. For example, the miR-29 compounds can reduce collagen expression by at least 10%, at least 20%, or at least 30%, or more, compared to native miR-29a. Suitable assays for assessing the reduction of collagen (col3a1) expression are known to those skilled in the art, such as the luciferase assay or qPCR assay described in Example 1 below. Protein levels can be assessed by methods well known in the art (e.g., Western blot).
[0089] The miR-29 compounds described herein are capable of cellular uptake, for example, they can be taken up in vivo by target cells (such as tenocytes or fibroblasts) without the use of transfection agents or other transfection vehicles such as liposomes.Conjugation of miR-29 compounds with lipophilic moieties, such as cholesterol moieties, enhances cellular uptake.The ability of cellular uptake can be evaluated by methods known to those skilled in the art, for example, by measuring miR-29 activity in an in vitro collagen 3 luciferase reporter assay.
[0090] The miR-29 compounds described herein are stable. Stable miR-29 compounds substantially retain activity in an in vitro collagen 3 luciferase reporter assay after storage at 37° C. for 3 months.
[0091] The miR-29 compounds described herein are also stable in the sense that they have a longer in vivo half-life as a result of the 2' sugar modifications, compared to unmodified (native) miR-29.
[0092] Double-stranded RNA can stimulate innate immune responses in mammals. For example, it has been reported that miR-29a can bind to receptors of the Toll-like receptor (TLR) family in immune cells and cause inflammatory responses (Reference 5). Immune stimulation can significantly limit the in vivo application of miRNA therapy. Therefore, compounds that can effectively mediate miRNA activity while avoiding or minimizing immune activation are desirable. The miR-29 compounds provided herein are non-immunogenic when administered to a subject, e.g., a human subject. Suitable assays for assessing non-immunogenicity are known to those skilled in the art, such as the TNF-α assay using human macrophages described in Example 1 below. Preferred compounds do not induce TNF-α expression, or they induce TNF-α expression of 10 pg / ml or less, when measured in the supernatant of cultured primary human macrophages 24 hours after treatment with the compound.
[0093] Because the compounds described herein do not induce undesirable immune responses, the compounds do not need to be protected from recognition by the immune system by encapsulation in liposomes or similar means. Thus, the compounds described herein are effective in vivo even when administered in a simple aqueous carrier, such as PBS. This greatly simplifies the preparation and administration of therapeutics and avoids the introduction of additional foreign components into the subject, which may raise safety concerns. Thus, the compounds described herein effectively mimic the function of natural miR-29 (e.g., miR-29a), but have the advantages of being more active, stable, and non-immunogenic. Examples also show that the compounds can be anti-inflammatory.
[0094] Therefore, the exemplary miR-29 compounds described in the Examples are chemically synthesized mimics of miR-29 with improved stability, activity, and cellular uptake, while remaining non-immunogenic. The nucleobase sequence of the compounds is closest to that of miR-29a, but as mentioned above, functional mimicry can also be extended to other miR-29 family members. The miR-29 compounds are stable in aqueous carriers and maintain activity even after storage at 37°C for 3 months. To enhance stability and activity, certain miR-29 compounds are chemically modified by introducing 2'-fluoro and 2'-O-methyl groups into the guide strand and 2'-O-methyl groups into the passenger strand. The passenger strand may further contain a 3' cholesterol group to enhance cellular uptake.
[0095] Administration of the compounds to sites of collagen dysregulation, such as injured tendons or fibrous tissue, restores miR-29a function. The miR-29 compounds described herein have a clearly defined mode of action. The compounds directly target key pathways in collagen production associated with various pathogenic conditions, including tendon injuries such as tendinopathy and other diseases that require reduced or inhibited collagen (particularly collagen 3) production, such as tissue fibrosis. Furthermore, treatment with the miR-29 compounds described herein does not require invasive procedures and can be delivered at the time of initial diagnosis, thereby initiating recovery very early.
[0096] As described in the Examples, in vitro and in vivo assays demonstrated that the miR-29 compounds described herein can significantly reduce collagen 3 expression, for example, in tenocytes and fibroblasts. The Examples also show that a single intratendinous injection of the miR-29 compounds significantly reduced collagen 3 expression and improved tendon structure in a mouse tendon injury model.
[0097] From a safety perspective, studies in rats and dogs monitored various characteristics, including clinical observations, body weight, hematology, coagulation, and clinical chemistry parameters, and gross necropsy findings during the acute phase and after a 14-day follow-up period. These studies were also designed to demonstrate safety pharmacology, and no changes were observed in the Irwin behavioral profile in rats or any cardiovascular effects in telemetered dogs. Respiratory parameters in rats remained unaffected. The examples also show that after local (intralesional) administration, negligible distribution in other tissues was observed, and any systemic miR-29a was rapidly degraded. Both in vitro and in vivo data in isolated human macrophages and a mouse tendon injury model provided evidence that the miR-29 compounds described herein are non-immunogenic. Furthermore, treatment with the miR-29 compounds described herein did not exhibit any off-target effects.
[0098] The present inventors have found that double-stranded miR-29 compounds (including a guide strand and a passenger strand) are more active than single-stranded miR-29 compounds (including only a guide strand; for example, Teno36 in Example 1). Thus, the miR-29 compounds described herein are typically double-stranded. The two strands are substantially complementary to each other so that they form a duplex.
[0099] length The guide strand can be 20 to 24 linked nucleosides in length. For example, the guide strand can be 20, 21, 22, 23, or 24 linked nucleosides in length. In one embodiment, the guide strand is 20 to 23 linked nucleosides in length. In one embodiment, the guide strand is 20 to 22 linked nucleosides in length. In one embodiment, the guide strand is 21 to 23 linked nucleosides in length. In one embodiment, the guide strand is 21 or 22 linked nucleosides in length. In one embodiment, the guide strand is 22 or 23 linked nucleosides in length. In a preferred embodiment, the guide strand is 22 linked nucleosides in length.
[0100] The passenger strand can be 19-23 or 20-24 linked nucleosides in length. For example, the passenger strand can be 19, 20, 21, 22, 23, or 24 linked nucleosides in length. In one embodiment, the passenger strand is 19-22 linked nucleosides in length. In one embodiment, the passenger strand is 19-21 linked nucleosides in length. In one embodiment, the passenger strand is 20 or 21 linked nucleosides in length. In one embodiment, the passenger strand is 21 or 22 linked nucleosides in length. In a preferred embodiment, the passenger strand is 21 linked nucleosides in length.
[0101] overhang The guide strand and passenger strand of miR-29 compound form a duplex by the sequence complementarity between the oligonucleotides of guide strand and passenger strand.The guide strand and passenger strand can form a duplex such that the guide strand has, for example, two nucleosides 3' overhang with the passenger strand, and the passenger strand has, for example, one nucleoside 3' overhang with the guide strand.The guide strand and passenger strand can form a duplex such that the guide strand has, for example, two nucleosides 3' overhang with the passenger strand.
[0102] mismatch When aligned, i.e., duplexed, mismatches can exist between corresponding nucleobases of the guide strand and passenger strand. A mismatch exists when corresponding nucleobases are not complementary. Complementary nucleobases are U and A, and C and G. For example, 3 to 8 mismatches can be present, e.g., 3, 4, 5, 6, 7, or 8 mismatches. In one embodiment, 3 to 6 mismatches are present. In one embodiment, 5 or 6 mismatches are present. In one embodiment, 6 mismatches are present. For example, mismatches can be at positions 3, 10-12, 18, and 20 (numbering relative to the passenger strand). The inventors surprisingly found that miR-29 compounds containing mismatches between the guide strand and passenger strand have higher activity (e.g., as measured by collagen 3 luciferase assay) compared to miR-29 compounds with fewer or no mismatches.
[0103] Conjugates The miR-29 compounds described herein can comprise one or more conjugate groups that are covalently attached to the oligonucleotide(s) of the compound.An exemplary conjugate group is a cholesterol moiety, but other conjugate moieties that improve the pharmacological properties (e.g., cellular uptake) of oligonucleotides are known in the art and can be used instead of cholesterol moieties.Therefore, the conjugate group is typically a lipophilic moiety.
[0104] In one embodiment, the miR-29 compound comprises a cholesterol moiety covalently attached to one or more oligonucleotide strands of the miR-29 compound. In one embodiment, the cholesterol moiety is covalently attached to the passenger strand. In one embodiment, the cholesterol moiety is covalently attached to the passenger strand, and the guide strand is not conjugated. In one embodiment, the cholesterol moiety is covalently attached to the 3' end of the passenger strand. In any of these embodiments, the cholesterol moiety can be attached via a linker, such as triethylene glycol. Thus, in one embodiment, the cholesterol moiety is a triethylene glycol cholesterol moiety. An exemplary cholesterol moiety is 3'phosphopropyl-2-ol,2,2'-[ethane-1,2-diylbis(oxy)]di(ethan-1-ol),10-O-[1-propyl-3-N-carbamoylcholesteryl].
[0105] salt The miR-29 compounds described herein can be provided as salts. Thus, the term "compound" includes the salts of the compounds. The salts are pharmaceutically acceptable salts, i.e., the salts retain the biological activity of the compound and do not have any toxicological effect on it. Examples of pharmaceutically acceptable salts include sodium salts and potassium salts. In one embodiment, the miR-29 compound is a sodium salt.
[0106] CWT-001 The specific miR-29 compound described in the examples is CWT-001. CWT-001 is a double-stranded chemically modified mimic of at least miR-29a, comprising a guide (antisense) strand and a passenger (sense) strand in a 1:1 ratio. The nucleic acid base sequences and chemical modifications of the guide and passenger strands correspond to those of "Teno18" (T18).
[0107] CWT-001 Guide Chain CWT-001 inhibits the expression of at least the same target genes as naturally occurring miR-29a, including collagen 3. The sugar residues are chemically modified by the introduction of 2'-fluoro and 2'-O-methyl groups, which enhance the stability and activity of the compound. The guide strand of CWT-001 has the same nucleobase sequence as the naturally occurring guide strand of human mature miR-29a ("hsa-miR-29a-3p"), which is: 5'-UAGCACCAUCUGAAAUCGGUUA-3' (SEQ ID NO: 1) is.
[0108] Each nucleoside is a 2'-substituted nucleoside, meaning that the nucleoside comprises a sugar moiety that includes at least one 2' substituent other than H or OH. The guide strand of CWT-001 has the formula: 5'-fUfAfGfCfAfCfCfAfUfCfUfGfAfAfAfUfCfGfGfUmUmA-3' In the formula, "f" represents a nucleoside containing a fluorine atom at the 2' position of the ribose ring, and "m" represents a nucleoside containing an O-methyl group at the 2' position of the ribose ring.
[0109] The internucleoside linkages are entirely phosphodiester internucleoside linkages.
[0110] The chemical name of the CWT-001 guide strand, optionally as a salt, e.g., sodium salt, is: RNA (5'phospho(2'deoxy-2'fluoro)U-(2'deoxy-2'fluoro)A-(2'deoxy-2'fluoro)G-(2'deoxy-2'fluoro)C-(2'deoxy-2'fluoro)A-(2'deoxy-2'fluoro)C-(2'deoxy-2'fluoro)C-(2'deoxy-2'fluoro)A-(2'deoxy-2'fluoro)U-(2'deoxy-2'fluoro)C-(2'deoxy-2'fluoro)U-( (2'deoxy-2'fluoro)U-(2'deoxy-2'fluoro)G-(2'deoxy-2'fluoro)A-(2'deoxy-2'fluoro)A-(2'deoxy-2'fluoro)A-(2'deoxy-2'fluoro)U-(2'deoxy-2'fluoro)C-(2'deoxy-2'fluoro)G-(2'deoxy-2'fluoro)G-(2'deoxy-2'fluoro)U-(2'deoxy-2'Omethyl)U-(2'Omethyl)A).
[0111] The structural formula of the CWT-001 guide chain as a free acid is shown below: [ka]
[0112] The structural formula of the CWT-001 guide chain in its ionized form (i.e., the anion of the salt) is shown below: [ka]
[0113] The structural formula of the CWT-001 guide strand as the sodium salt is shown below and in Figure 1A: [ka]
[0114] CWT-001 Passenger Chain The passenger strand of CWT-001 has the same nucleobase sequence as the naturally occurring passenger strand of human mature miR-29a ("hsa-miR-29a-5p"), except that the 3'-terminal G is not present in CWT-001. Thus, the nucleobase sequence of the CWT-001 passenger strand is as follows: 5'-ACUGAUUUCUUUUGGUGUUCA-3' (SEQ ID NO: 3).
[0115] The passenger strand contains nucleosides containing modified sugar moieties (2'-O-methyl), nucleosides containing unmodified sugar moieties, and nucleosides containing deoxyribose sugar moieties. The passenger strand of CWT-001 has the formula: 5'-mArCmUrGmArUmUrUmCrUmUrUmUrGmGrUmGrUmUrCdA-3' In the formula, "m" denotes a nucleoside containing an O-methyl group at the 2' position of the ribose ring, "r" denotes a ribonucleoside, i.e., a nucleoside containing an OH group at the 2' position of the ribose ring, and "d" denotes a deoxyribose nucleoside.
[0116] The internucleoside linkages are entirely phosphodiester internucleoside linkages.
[0117] The passenger strand of CWT-001 contains a cholesterol moiety, e.g., a triethylene glycol cholesterol moiety, covalently attached to the 3' end of the passenger strand. The cholesterol moiety improves the pharmacological properties of the miR-29a compound, e.g., the cholesterol moiety increases the cellular uptake of oligonucleotides.
[0118] The chemical name of the CWT-001 passenger chain as the sodium salt is: RNA((2'OM methyl)AC-((2'OM methyl)UG-(2'OM methyl)AU-(2'OM methyl)UU-(2'OM methyl)CU-(2'OM methyl)UU-(2'OM methyl)UG-(2'OM methyl)GU-(2'OM methyl)GU-(2'OM methyl)UC-(2'deoxy)A-3'phosphopropyl-2-ol,2,2'-[ethane-1,2-diylbis(oxy)]di(ethan-1-ol), 10-O-[1-propyl-3-N-carbamoylcholesteryl] (optionally as a salt, for example the sodium salt).
[0119] Thus, a passenger strand comprising a cholesterol moiety (e.g., a triethylene glycol cholesterol moiety) covalently attached to the 3' end of the passenger strand may also be represented by the formula: 5'-mArCmUrGmArUmUrUmCrUmUrUmUrGmGrUmGrUmUrCdAchol-3
[0120] The structural formula of the CWT-001 passenger chain as a free acid is shown below: [ka]
[0121] The structural formula of the CWT-001 passenger chain in its ionized form (i.e., the anion of the salt) is shown below: [ka]
[0122] The structural formula of the CWT-001 passenger chain as the sodium salt is shown below and in Figure 1B: [ka]
[0123] Details of CWT-001 are shown in Table A below. [Table 1]
[0124] Methods of Treatment and Therapeutic Uses of MicroRNA-29 Compounds and Compositions The compounds and compositions described herein are particularly suitable for treating diseases associated with local dysregulation of collagen, characterized by the local overproduction of one or more types of collagen fiber.For example, the miR-29 compounds described herein reduce or inhibit the expression of collagen 3, as assessed by, for example, luciferase assay.Therefore, the miR-29 compounds described herein can be useful in treating diseases that require the reduction or inhibition of the expression of one or more types of collagen fiber, for example, collagen 3 (col3a1).
[0125] Three exemplary diseases are described below: tendon injuries (particularly tendinopathy), Peyronie's disease and Dupuytren's disease. Peyronie's disease and Dupuytren's disease are examples of tissue fibrosis.
[0126] tendon injury Tendons are connective tissues that attach muscles to bones. Tendon tissue is composed of approximately 30% collagen and 2% (wet weight) elastin embedded in an extracellular matrix containing various types of cells, particularly tenocytes. The predominant collagen is type 1 collagen, which has a large diameter (40–60 nm) and connects to each other to form tightly packed fiber bundles. Type 3 collagen is also present, which has a smaller diameter (10–20 nm) and forms a looser network of bundles. Healthy tendons primarily contain well-arranged collagen 1 (Col1) fiber bundles (approximately 95%), interspersed with a small amount of biomechanically inferior collagen 3 (Col3) fibers (approximately 5%). In healthy tendons, miR-29 (e.g., miR-29a) directly suppresses collagen 3 overproduction, angiogenesis, tenocyte hyperproliferation, and adhesion formation by targeting Col3a1, VEGFA, AKT3, and TGFB2, respectively. The sequence of miR-29a and its binding sites in these target mRNAs are conserved among mammalian species.
[0127] The biomechanical properties of tendons, particularly their tensile strength, are related to their cross-sectional area (i.e., thickness), collagen content, and the ratio between different types of collagen.
[0128] As mentioned above, healthy tendons are composed primarily of well-arranged collagen type 1 (Col 1) fiber bundles (approximately 95%), interspersed with a small amount of biomechanically inferior collagen type 3 (Col 3) fibers (approximately 5%). After acute injury, during tendinopathy, and during tendon injury healing, a shift in collagen synthesis occurs from type 1 to type 3 collagen. A continuous increase in type 3 collagen synthesis leads to a long-term imbalance in collagen ratios. This has significant and detrimental effects on the biomechanical properties of tendons. In particular, it reduces the tendon's tensile strength and its ultimate rupture strength, thereby predisposing it to subsequent rupture.
[0129] Tendon injuries can be caused by or associated with a number of factors, including but not limited to external trauma, mechanical stress (such as overuse), degeneration, inflammation, and combinations thereof. Tendinopathy is the medical name for diseases associated with tendon overuse and injury.
[0130] Overuse tendinopathy is a complex, multifaceted pathology of tendons that is clinically diagnosed after the gradual onset of activity-related pain, decreased function, and, in some cases, localized swelling of the tendon. Overuse, repeated strain, or trauma results in the breakdown of collagen fibers in the tendon. In response to this damage, tenocytes initiate a repair response, initially producing high levels of collagen 3, which acts as a "patch" to rapidly restore tendon function. Over time, collagen 3 gradually replaces collagen 1. However, because collagen 3 is biomechanically inferior to collagen 1, tendons are prone to further damage, triggering the production of more collagen 3. In tendinopathy, a vicious cycle of further injury and decreased healing leads to a lesion characterized by increased collagen 3 (approximately 30%), cell density, vascularization, inflammation, and adhesion formation.
[0131] Conventional treatments for tendinopathy, such as steroid injections, are generally employed empirically to combat pain and inflammation, but they do not alter the tissue structure of the tendon. However, these treatments are not completely satisfactory, and recurrence of symptoms is common.
[0132] The following examples demonstrate, inter alia, that the miR-29 compounds provided herein are safe and effective in reducing or inhibiting collagen 3 expression in vivo, including in mouse models of tendinopathy. For example, using a mouse model, Figure 4 shows that treatment with an exemplary miR-29 compound (CWT-001) according to the present invention significantly improved tendon fiber alignment and collagen production in tendon disease through suppression of collagen 3 expression. Furthermore, the inventors have previously shown that the equine collagenase-induced tendinopathy (SDFT) model mirrors human tendinopathy, with decreased miR-29a expression and a concomitant increase in the Col3:Col1 ratio after tendon injury. A single intralesional injection of a miR-29 compound reduced collagen 3 expression and lesion size and improved tendon structure (see Reference 3). Collectively, these data provide a rationale for safe and effective human therapies using miR-29 compounds, including those provided herein. Given the experiments described herein (see Examples), doses in the μg and low mg range are expected to be well tolerated in animal species and can be administered in volumes that are easily and safely injectable (e.g., approximately 1 ml). In a Phase 1 randomized, double-blind, placebo-controlled study in human subjects with lateral epicondylitis, doses of 200 μg, 500 μg, and 1500 μg of CWT-001 administered in a 1 ml volume were found to be safe and effective (see Example 7).
[0133] Therefore, the miR-29 compounds and compositions of the present invention can be used to treat tendon disorders, such as overuse tendon disorders. The subject may be a human subject. The subject may have subacute tendon disorders. Treatment with the compounds and compositions of the present invention may reduce progression to chronic tendon disorders. The subject may have chronic tendon disorders. The subject may have activity-induced tendon disorders. The subject may have a partial tendon rupture. Treatment may reduce progression to complete tendon rupture.
[0134] The method of the present invention can be applied to any injured tendon. The main tendons affected by tendinopathy in humans are the Achilles tendon, supraspinatus tendon, common flexor tendon, common extensor tendon, patellar tendon, and gluteal tendon. The main tendon affected by tendinopathy in equine subjects is the superficial flexor tendon. In certain embodiments, one or more of these tendons are the target of treatment.
[0135] Thus, the tendon injury may be lateral epicondylitis, medial epicondylitis, rotator cuff tendinopathy, common extensor origin tendinopathy, common flexor origin tendinopathy, gluteal tendinopathy (greater trochanteric pain syndrome, GTPS), patellar tendinopathy, jumper's knee, plantar fasciitis, Achilles tendinopathy, peroneal tendinopathy, supraspinatus syndrome, or a combination thereof. In one embodiment, the tendon injury is an upper limb tendinopathy (including lateral epicondylitis, golfer's elbow, rotator cuff tendinopathy, and De Quervain's disease). In a specific embodiment, the tendon injury is lateral epicondylitis.
[0136] Treatment with miR-29 compounds promotes regeneration or repair of affected tissues, for example, in tendons, tunica albuginea, or plantar fascia.
[0137] Treatment with miR-29 compounds reduces the expression of collagen, eg, collagen 3, at the site of treatment.
[0138] The methods of the present invention can be applied at any stage of tendon injury or at any stage of the healing process of an injured tendon. In one embodiment, the miR-29 compounds and compositions of the present invention are administered to a subject at the time of initial diagnosis.
[0139] The subject, for example, a human subject, may not have responded to previous treatment, or may have had an insufficient response, or may have been intolerant to previous treatment.This means that the subject's symptoms persist despite treatment.Previous treatment for tendinopathy may include one or more of: physical therapy, splinting, treatment with nonsteroidal anti-inflammatory drugs (NSAIDs), and local injection of corticosteroids into the affected tendon.The subject may have failed conservative treatment, i.e., symptoms persist for more than 3 months despite treatment.
[0140] The efficacy of miR-29 treatment in tendon injuries (e.g., tendinopathy such as elbow tendinopathy) can be assessed based on one or more of the following (see also Example 7): - Reduction in pain, e.g., as measured using a visual assessment scale (VAS), e.g., at 14, 28, and / or 90 days after administration of the miR-29 compound or salt thereof; - improvement in disability and symptoms, e.g., as measured using the Disabilities of the Arm, Shoulder, and Hand (Quick DASH) score and / or the American Shoulder and Elbow Surgeons Elbow (ASES-E), e.g., at 14, 28, and / or 90 days after administration of the miR-29 compound or salt thereof; - improvement in pain and disability, e.g., as measured by Patient Rated Tennis Elbow Evaluation (PRTEE), e.g., at 14, 28, and / or 90 days after administration of the miR-29 compound or salt thereof; and - Improvement in the treated tendon(s), e.g., as measured by ultrasound assessment, at 14, 28, and / or 90 days after administration of the miR-29 compound or salt thereof.
[0141] Dupuytren's disease Dupuytren's disease (DD) affects the fibrous layer of tissue underlying the skin of the palm and fingers, also known as the "fascia" or "palmar fascia." In subjects with DD, the fascia thickens and hardens over time. This causes the fingers to pull inward, toward the palm, resulting in a condition known as Dupuytren's contracture. Subjects with DD may be unable to perform certain daily activities. Non-surgical (e.g., steroid or collagenase injections) and surgical treatment options are available to help slow the progression of the disease and improve movement in affected fingers, but these can have significant side effects or complications.
[0142] At the molecular level, DD is characterized by an abnormal proliferation process of fibroblasts and the overproduction of collagens, including collagen 3. (Reference 6) The miR-29 compounds described herein are believed to be effective in treating Dupuytren's disease based on their ability to specifically and safely inhibit local collagen (e.g., collagen 3) expression in fascia, thus counteracting the formation of fibrous tissue characteristic of this disease.
[0143] The efficacy of miR-29 treatment in Dupuytren's disease can be assessed based on the improvement of disability and symptoms, for example, using the Disabilities of the Arm, Shoulder, and Hand (Quick DASH) score, symptom and / or pain relief (VAS score), and clinical assessment of the reduction of Dupuytren's nodes and cord formation (e.g., by improvement in the Tubiana grading system). See, for example, Reference 7.
[0144] Peyronie's disease Peyronie's disease (PD) is a progressive fibrotic disorder characterized by the formation of scars or plaques within the tunica albuginea (TA) of the penis. This condition can be extremely debilitating, both physically and mentally, due to progressive penile pain and penile deformity.
[0145] Excessive local accumulation of collagen 3 and other components of the extracellular matrix is a hallmark of this disease. Fibrotic tissue is associated with a shift from the normal collagen 3 / 1 ratio to increased collagen 3 content. For example, PD animals have been shown to develop fibrosis in the tunica albuginea and subalbuginea regions, accompanied by a marked upregulation of collagen 3 protein. Furthermore, the collagen 3 / 1 ratio was higher in the PD group compared with the control group (P<0.05) (Reference 8). The miR-29 compounds described herein are particularly effective and safe in inhibiting local collagen 3 expression in the TA, and therefore are believed to be effective in treating Peyronie's disease based on their ability to counteract the formation of fibrotic tissue characteristic of this disease.
[0146] Co-occurrence of Dupuytren's disease and Peyronie's disease is common (e.g., Reference 9), and both diseases are associated with overproduction of collagen 3 (Reference 10). Data suggest that they share common pathophysiology and may be amenable to the same treatment regimens. This further supports the therapeutic efficacy of miR-29 mimetics, including those provided herein, in the treatment of Peyronie's disease and Dupuytren's disease.
[0147] The efficacy of miR-29 treatment in Peyronie's disease can be assessed based on disability, improvement in symptoms and / or pain relief, improvement or lack of progression of penile curvature, and improvement in duplex ultrasound.
[0148] Target of treatment The subject is typically a human. However, the methods of the present invention can be extended to any other mammal, including other primates (particularly great apes such as gorillas, chimpanzees, and orangutans, as well as Old World and New World monkeys) and rodents (including mice and rats), as well as other common laboratory, livestock, and agricultural animals (including, but not limited to, rabbits, dogs, cats, horses, cattle, sheep, and goats). Another preferred subject is a horse, particularly one bred for equine sport.
[0149] Pharmaceutical Compositions and Administration The miR-29 compounds or their salts described herein can be formulated into pharmaceutical compositions. These compositions may contain, in addition to the miR-29 compounds or their salts, pharmaceutically acceptable excipients, carriers, buffers, stabilizers, or other substances known to those skilled in the art. Such substances are non-toxic and do not interfere with the effectiveness of the miR-29 compounds.
[0150] Thus, in one embodiment, the pharmaceutical composition comprises a miR-29 compound or a salt thereof and a pharmaceutically acceptable carrier or diluent, such as a sterile liquid carrier, e.g., an injectable solution. The pharmaceutically acceptable carrier or diluent may comprise saline. The pharmaceutically acceptable carrier or diluent may also be a sterile aqueous solution, e.g., phosphate-buffered saline (PBS). The pharmaceutically acceptable carrier or diluent may also be a sterile aqueous solution, e.g., a sodium chloride solution, such as isotonic saline (e.g., 0.9% w / v NaCl). In one embodiment, the pharmaceutical composition comprises a miR-29 compound or a salt thereof, and further comprises a sodium chloride solution, such as PBS and isotonic saline (e.g., 0.9% w / v NaCl).
[0151] Considering the local nature of the condition to be treated, local administration, for example by local injection, is particularly suitable.Therefore, the compound and composition of the present invention are typically administered locally (intralesionally) at the affected site.For example, injection can be delivered into the affected tendon.Injection into the affected tendon is also known as intratendinous administration.
[0152] For injection at the affected site, the miR-29 compound may be included in a pharmaceutical composition further comprising a parenterally acceptable aqueous solution. The solution is sterile. The solution is pyrogen-free and has suitable pH, isotonicity, and stability. Those skilled in the art can prepare a suitable solution using an isotonic vehicle, such as phosphate-buffered saline, sodium chloride solution, Ringer's solution, or lactated Ringer's solution. Preservatives, stabilizers, buffers, antioxidants, and / or other additives may be included as needed. For example, EDTA may be added at a final concentration of, for example, 0.001% to 0.005%, e.g., 0.003% (100 μM). A specific formulation of the compound of the present invention is an injectable solution, such as a solution comprising the miR-29 compound or salt of the present invention and PBS, optionally further comprising EDTA.
[0153] Injections into tendons are typically ultrasound-guided, for example, using the "peppering technique" (Reference 11). The "peppering technique" is an injection method in which small injections are administered multiple times by withdrawing, reorienting, and reinserting a needle without the needle ever leaving the skin. In the setting of injured / chronic tendons, this can be advantageous for stimulating a healing response. Thus, in one embodiment, a single dose of miR-29 compound is administered intratendinously in the form of multiple needle injections at different sites within the injured tendon.
[0154] Examples of routine techniques and protocols can be found in Remington's Pharmaceutical Sciences, 22nd Edition, 2012.
[0155] Dosage and Treatment Regimen Those skilled in the art know that dosage can be expressed in various ways.Unless otherwise specified, the dosage of miR-29 compounds shown herein refers to the weight of the oligonucleotide portion of the guide strand and passenger strand (i.e., excluding any conjugate group such as cholesterol moiety) as free acid.The reference compound is CWT-001 as free acid and excluding triethylene glycol cholesterol moiety.The equivalent dosage of the salt and / or conjugate form of miR-29 compounds, which may have different molecular weights, can be calculated by those skilled in the art.Equivalent dosage can also be expressed in molar amount (e.g., nMole) or molar concentration (e.g., nM).Those skilled in the art know how to convert between these different units.
[0156] In the examples and figures described below, the dosage shown refers to the free acid of the cholesterol conjugate form of compound.Therefore, when examples and figures refer to 200 μ g or 200 μ g / ml, this corresponds to about 190 μ g or 190 μ g / ml of the compound as free acid, excluding cholesterol moiety;When examples refer to 500 μ g or 500 μ g / ml, this corresponds to about 475 μ g or 475 μ g / ml of the compound as free acid, excluding cholesterol moiety;When examples refer to 1500 μ g or 1500 μ g / ml, this corresponds to about 1420 μ g or 1420 μ g / ml of the compound as free acid, excluding cholesterol moiety;When examples refer to 2000 μ g or 2000 μ g / ml, this corresponds to about 1900 μ g or 1900 μ g / ml of the compound as free acid, excluding cholesterol moiety, etc. If the cholesterol moiety is excluded, this also excludes any linker (eg, triethylene glycol) between the cholesterol moiety and the oligonucleotide portion of the compound.
[0157] Administration is typically a "therapeutically effective amount" or a "prophylactically effective amount" (although in some cases treatment can include prevention), which is sufficient to show benefit to the subject. For example, a therapeutically effective amount is the amount of a miR-29 compound or salt thereof that, when administered to a subject, results in amelioration of disease symptoms, e.g., reduction in pain or disability, improved functionality, and / or prevents or delays disease progression.
[0158] The miR-29 compounds can be administered directly into the damaged tissue, i.e., intralesionally, typically by injection, for example, using a needle.
[0159] In one embodiment, therapeutic effect can be achieved by only single administration of the dose described herein. " Single " administration means that only one dose of compound is required to achieve therapeutic effect.Therefore, the subject typically does not need to return to the second administration to experience the improvement of disease symptoms at the administration site of the first administration.
[0160] General The practice of the present invention will employ, unless otherwise indicated, conventional methods of chemistry, biochemistry, molecular biology, immunology and pharmacology, within the skill of the art.
[0161] The term "comprising" encompasses "including" as well as "consisting", e.g., a composition "comprising" X may consist solely of X, or may include something additional, e.g., X+Y.
[0162] The term "about" in reference to a numerical value x is arbitrary and means, for example, x + / - 10%.
[0163] The term "substantially" does not exclude "completely." If necessary, the term "substantially" may be omitted from the definition of the invention.
[0164] References to a percentage of sequence identity between two oligonucleotide sequences mean that, when aligned, that percentage of nucleobases are the same comparing the two sequences over the entire length of those sequences.
[0165] The following examples are provided to illustrate various embodiments of the present invention. The examples are illustrative and are not intended to limit the invention in any way. [Brief explanation of the drawings]
[0166] [Figure 1] (A) Structure of the CWT-001 guide (antisense) strand as the sodium salt. (B) Structure of the CWT-001 passenger (antisense) strand as the sodium salt. [Figure 2] Luciferase activity in HEK293 cells co-transfected with luciferase plasmids containing human collagen 3 miR29 binding sites and miR29a compounds as indicated, and controls (n=4). Luciferase activity is inversely proportional to miR29a activity. [Figure 3] (A) Selected miR29 compounds were tested for potential immunogenicity by assessing their ability to induce production of the proinflammatory cytokine TNF-α in primary human macrophages. Untreated cells ("Untreated") were used as a negative control. Cells treated with 2.5 μg / ml of imiquimod ("IMQ2.5") were used as a positive control. (B) Selected miR29 compounds were tested for their ability to knock down col3a1 expression in human tendon cells. Scrambled miR29a ("scr") and untreated cells ("untr") were used as negative controls. (C) Luciferase activity of HEK293 cells cotransfected with a luciferase plasmid containing human collagen 3 miR29 binding sites and selected miR-29 compounds as indicated. Scrambled miR29a ("scr") was used as a negative control. Significance was assessed using a one-way ANOVA test. ***P≦0.001 compared to Teno20, n=3. (D) Col3a1 transcript levels measured by quantitative PCR after tenocyte treatment with the indicated cholesterol-conjugated miR-29 compounds. Values are normalized to GAPDH and shown as relative expression compared to untreated samples. Student's t-test, *P≦0.05 Teno18 compared to Teno33 on day 5, n=3. (E) Selected miR-29 compounds were tested in a mouse tendon injury model. Compounds were injected directly into the injured patellar tendon, and mice were allowed to recover for 1, 3, or 7 days. Absolute Col3a1 transcript numbers were measured by q-PCR. Significance was assessed using a one-way ANOVA test. *P≦0.05, **P≦0.01 Teno18 compared to Teno20 at each time point, n=4. [Figure 4] Histological and molecular analysis of mouse tendons after induction of tendon injury followed immediately by treatment with CWT-001. (A) Absolute copy number of col3a1 mRNA in mouse patellar tendons 1, 3, and 7 days after injection of CWT-001 or PBS (n=3). (B) Representative H&E-stained sections of injured tendons after 7 days of treatment with CWT-001 (right) or PBS control (left). [Figure 5] Levels of the proinflammatory cytokine tumor necrosis factor alpha (TNF-a) in the supernatant of cultured primary human macrophages 24 h after treatment with CWT-001, scrambled negative control, or PolyIC positive control, as measured by ELISA. [Figure 6] Expression levels of interferon-inducible genes OAS2 (A), INFa (B), IFTM1 (C), MX1 (D), IRF9 (E), and OAS1 (F) in cultured primary human macrophages 24 hours after treatment with CWT-001 (middle bar) or Poly IC positive control (right bar), measured by qPCR and expressed as fold change relative to the untreated control (left bar). "No TF" = no transfection reagent (cellular uptake was enhanced by the cholesterol moiety). [Figure 7] Expression levels of interferon-inducible genes MX1 (A), OAS2 (B), IFITM1 (C), and IRF9 (D) in mouse tendons 0, 1, 3, and 7 days after intratendinous injection of CWT-001 or PBS negative control, measured by qPCR and expressed as absolute copy numbers of interferon-responsive genes per 10 copies of 18S. [Figure 8] Levels of miR29a in fresh human serum incubated with 0, 2, 20, and 100 μg / ml of CWT-001 for 0, 6, 12, and 24 h at 37°C, measured by qPCR, normalized to Cel39 spike in control, and shown as relative expression compared to untreated samples (n=3). [Figure 9] Levels of miR29a in fresh human serum incubated with 0, 2, 20, and 100 μg / ml CWT-001 at 37°C for 0 min, 15 min, 30 min, 45 min, 1 h, 6 h, 12 h, and 24 h, measured by qPCR, normalized to Cel39 spike in control, and expressed as fold change relative to untreated samples (n=3). [Figure 10]miR29a levels in kidney (A), spleen (B), liver (C), serum (D), lung (E), muscle (F), and heart (G) of mice harvested 0, 1, 4, and 7 days after intravenous injection of CWT-001, as measured by qPCR. Organ miR29a expression levels were normalized to GAPDH and shown as relative fold change compared to untreated controls. Serum miR29a expression levels were normalized to Cel39 spike-in control and shown as fold change compared to PBS controls (n=4). [Figure 11] Serum levels of miR29a in blood collected from mice at 0 min, 15 min, 30 min, 1 h, 2 h, 4 h, 6 h, 24 h, and 72 h after injection of CWT-001 into the patellar tendon (n=4), measured by qPCR, normalized to Cel39 spike in control, and expressed as fold change relative to PBS-treated control. [Figure 12] Levels of miR29a in mouse serum (A), lung (B), skin proximal to the tendon injection (C), kidney (D), spleen (E), muscle (F), liver (G), heart (H), and bone marrow (I) collected 7 days after intravenous injection of 4, 20, 40, and 50 mg / ml of CWT-001 or PBS control, as measured by qPCR. Organ miR29a expression levels were normalized to GAPDH and shown as relative fold change compared to untreated controls. Serum miR29a expression levels were normalized to Cel39 spike-in control and shown as fold change compared to PBS control (n=4). [Figure 13] Study design for a Phase 1, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, and pharmacokinetics of single ascending doses of CWT-001 injection in human subjects with lateral epicondylitis. [Figure 14] Ultrasound images (A and B) show probe placement during administration of CWT-001 into the common extensor tendon. The radial head (r), radiohumeral joint (j), lateral epicondyle, and common extensor tendon are visualized. The probe is placed along the lateral side of the elbow parallel to the longitudinal axis of the common extensor tendon. [Figure 15]Comparison of miR29a levels in healthy and Dupuytren's human fascial tissue as measured by qPCR (n=4 healthy, n=3 Dupuytren's). [Figure 16] Collagen 1 (A) and collagen 3 (B) levels in human Dupuytren's fibroblasts after transfection with 5 μM miR29a mimic, miR29b mimic, miR29c mimic, CWT-001, miR29a antagomir, or scrambled miR29a control, as measured by qPCR. miR29a expression levels were normalized to GAPDH and shown as relative fold change compared to the scrambled control (n=3). *P<0.05, **P<0.01, ***P<0.005 vs. scrambled control. (Student's t-test). [Figure 17] In this phase I, randomized, double-blind study, human subjects with lateral epicondylitis received a single 200 μg (n=6) (A), 500 μg (n=6) (B), or 1500 μg (n=6) (C) dose of CWT-001 administered via intratendinous injection or a matching placebo (n=2) (3:1). Subjects assessed pain using a 100-mm visual analog scale (VAS) once daily for the first 14 days after treatment and for the preceding 24 hours. From day 14 onward, subjects completed weekly pain diaries until day 90 after injection. The horizontal "MCID" line indicates the minimal clinically important difference (MCID) established for the VAS in the treatment of lateral epicondylitis. The mean change in VAS score for all subjects receiving any dose of CWT-001 (n=18) was compared to the mean change in VAS score for all subjects receiving placebo (n=6) (D), and in a separate study (E), the mean percent change in VAS score for all subjects receiving any dose of CWT-001 was compared to the mean percent change in VAS score for subjects treated with corticosteroids (n=50), platelet-rich plasma (PRP) (n=50), or xylocaine (n=50). [Figure 18]In this phase I, randomized, double-blind study, human subjects with lateral epicondylitis received a single 200 μg (n=6) (A), 500 μg (n=6) (B), or 1500 μg (n=6) (C) dose of CWT-001 administered via intratendinous injection or a matching placebo (n=2) (3:1). Subjects reported their physical function and symptoms using the QuickDASH index, and the change in QuickDASH score was plotted from pre-treatment day 1 to days 14, 28, and 90. The mean change in QuickDASH score for all subjects (n=18) receiving any dose of CWT-001 was compared with the mean change in QuickDASH score for all subjects (n=6) receiving placebo (D). The horizontal "MCID" line indicates the MCID established for QuickDASH in patients with upper limb musculoskeletal disorders. [Figure 19] In this phase I, randomized, double-blind study, human subjects with lateral epicondylitis received a single 200 μg (n=6) (A), 500 μg (n=6) (B), or 1500 μg (n=6) (C) dose of CWT-001 administered by intratendinous injection or a matching placebo (n=2) (3:1). Patient-rated tennis elbow evaluation (PRTEE) was used to measure perceived pain and disability in study subjects, and changes in PRTEE scores were plotted from pre-treatment day 1 to days 14, 28, and 90. The mean change in PRTEE score for all subjects (n=18) receiving any dose of CWT-001 was compared with the mean change in PRTEE score for all subjects (n=6) receiving placebo (D). [Figure 20]In this phase I, randomized, double-blind study, human subjects with lateral epicondylitis received a single 200 μg (n=6), 500 μg (n=6), or 1500 μg (n=6) dose of CWT-001 or a matching placebo (n=2) (3:1) administered via intratendinous injection. Ultrasound tissue characterization (UTC) was used to visualize tendon structure and quantify grayscale tendon matrix changes into four distinct echotypes related to tendon integrity. Types I and II represent organized matrix; types III and IV represent disorganized matrix (A). Representative ultrasound images of the lateral elbow are provided for subjects receiving placebo before injection (B), at day 28 (C), and at day 90 (D), and for subjects receiving 200 μg of CWT-001 before injection (E), at day 20 (F), and at day 90 (G). The percentages of UTC types I, II, III, and IV tendon tissue and the total percentages of repaired (UTC types I and II) versus degenerated (UTC types III and IV) tendons were quantified for subjects receiving 200 μg (H, I), 500 μg (J, K), or 1500 μg (L, M) doses of CWT-001 or matching placebo. The mean percentages of repaired and degenerated tendons for all subjects receiving any dose of CWT-001 (n = 18) were compared with the mean percentages of repaired and degenerated tendons for all subjects receiving placebo (n = 6). *P < 0.05, **P < 0.01.
[0167] Example Example 1: Evaluation of miR-29 compounds and primary pharmacological studies (Figures 1-3) A library of miR-29 mimetic compounds containing various chemical modifications (2'-fluororibose, 2'-O-methylribose, deoxyribose, and / or phosphorothioate) in various combinations was generated. All compounds except one (Teno36) are double-stranded compounds containing a guide strand and a passenger strand. The guide strand of each compound has a nucleobase sequence identical to that of the guide strand of native human mature miR-29a (hsa-miR-29a-3p; SEQ ID NO: 1). The passenger strand has a nucleobase sequence that is identical to that of the passenger strand of native human mature miR29a (hsa-miR-29a-5p; SEQ ID NO: 2), or it may lack the 3' G nucleotide (SEQ ID NO: 3) and / or it may have one or more nucleotide substitutions compared to the sequence of the native miR29a passenger strand (SEQ ID NOs: 4-6). See Table 1b. A negative control passenger strand representing the reverse sequence of SEQ ID NO:2 (SEQ ID NO:7) was also tested. Nucleobase sequences with optional sugar and internucleoside linkage (backbone) modifications are shown in Table 1a. For each compound, the first row represents the guide strand, and the second row represents the passenger strand. All sequences are shown in the 5' to 3' direction. SEQ ID NOs represent the nucleobase sequence (i.e., excluding chemical modifications). Teno46 contains no chemical modifications and therefore corresponds to native mature miR-29a. Teno39 has been previously described (Reference 2). The structure of an exemplary compound, Teno18, as its sodium salt, in which the passenger strand is conjugated to a cholesterol moiety at the 3' end, is shown in Figures 1A (guide strand) and 1B (passenger strand). [Table 2] TIFF2023547274000010.tif238162TIFF2023547274000011.tif190162
[0168] Therefore, the following passenger strand nucleobase sequences were tested (see Table 1b): SEQ ID NO: 2 represents the native human miR-29a passenger strand sequence. SEQ ID NO: 3 differs from SEQ ID NO: 2 at one position, as underlined. SEQ ID NO: 4 differs from SEQ ID NO: 2 at five positions. SEQ ID NO: 5 differs from SEQ ID NO: 2 at six positions. SEQ ID NO: 6 differs from SEQ ID NO: 2 at seven positions. SEQ ID NO: 7 is the reverse sequence of SEQ ID NO: 2 and represents a negative control. [Table 3]
[0169] Table 1c below shows the combination of 2' sugar modification, nucleobase sequence (as SEQ ID NO), and internucleoside linkage for each compound. Teno1 through Teno49 contain one of five guide strands (hereafter referred to as G1 through G5) and one of eleven passenger strands (hereafter referred to as P1 through P11). Teno36 is an exception because it does not contain a passenger strand. All sequences are shown in the 5' to 3' direction.
[0170] Taking Teno1 as an example, Table 1c shows that it contains a "G1" guide strand having the nucleobase sequence of SEQ ID NO: 1, where the 3'-terminal three nucleosides are 2'-O-methyl ribonucleosides, the remaining nucleosides are unmodified ribonucleosides, and all internucleoside linkages are phosphodiester. The passenger strand is "P1," which contains the nucleobase sequence of SEQ ID NO: 2, where all nucleosides are alternating 2'-O-methyl and unmodified ribonucleosides, and all internucleoside linkages are phosphodiester. Teno2 contains the same guide strand ("G1") as Teno1, but a different passenger strand ("P2"), and so on. [Table 4] TIFF2023547274000014.tif242162TIFF2023547274000015.tif98160
[0171] Table 1d groups the compounds according to the passenger chain. [Table 5] TIFF2023547274000017.tif241161TIFF2023547274000018.tif97161
[0172] Compounds were tested for activity relative to native human mature miR29a using an in vitro collagen 3 luciferase reporter assay. The basis of this assay is a luciferase reporter gene containing a miR29a binding site derived from collagen 3. In this assay, luciferase activity is inversely proportional to miR29a activity. This means that higher miR29a activity more strongly suppresses collagen 3 expression, resulting in a lower luciferase signal. Luciferase assays were performed in HEK293 cells after transfection of miR-29 compounds with a transfection agent. The luciferase activity of miR-29 compounds is compared to cells treated with a commercially available human native miR29a positive control ("mir29a+ve") and a scrambled miR29a negative control ("scramble") (n=4). The results are shown in Figure 2.
[0173] References to "Chol.conj." in Figure 2 refer to a commercially available miR29a positive control that was conjugated to a cholesterol moiety at the 3' end of the passenger strand and added to HEK293 cells without a transfection agent. Figure 2 shows that the cholesterol-conjugated compound can enter cells and suppress collagen 3 expression. The higher luciferase signal with the cholesterol-conjugated compound compared to the unconjugated miR29a positive control likely reflects the effect of the transfection agent used to transfect the unconjugated miR29a positive control, whereas the transfection agent was absent when the cholesterol-conjugated compound was transfected.
[0174] Various compounds (Teno2, Teno5, Teno6, Teno7, Teno11, Teno12, Teno13, Teno15, Teno18, Teno19, Teno20, Teno25, Teno26, Teno27, Teno32, Teno33, and Teno34) were tested for potential immunogenicity by examining their ability to induce production of the proinflammatory cytokine TNFα in primary human macrophages. Cultured primary human macrophages, which are sensitive to ds-RNA molecules as key components of the innate immune system, were treated with 0.35 μg / ml of miR-29 compounds for 24 hours (n=4), and levels of the proinflammatory cytokine tumor necrosis factor alpha (TNFα) were measured by ELISA. Imiquimod (IMQ), a TLR7 / 8 agonist, was used as a positive control (2.5 μg / ml). The results are shown in Figure 3A. Compounds that induced expression of TNF-α above 10 pg / ml were not advanced, but Tenol2 was advanced because it was the least immunogenic miR-29 compound tested (Tenoll, Tenol2, and Tenol3), which contains a guide strand containing phosphorothioate internucleoside linkages.
[0175] Therefore, various compounds (Teno2, Teno9, Teno12, Teno15, Teno18, Teno19, Teno20, Teno33, and Teno38) were tested for their ability to inhibit col3a1 expression in human tenocytes. The results are shown in Figure 3B. This resulted in the selection of three miR-29 compounds: Teno18, Teno20, and Teno33. [Table 6]
[0176] The stability of Teno18, Teno20, and Teno33 was confirmed by measuring their activity in an in vitro collagen 3 luciferase reporter assay after storage at 37°C for 3 months. All compounds were stable. Teno18 and Teno33 showed the highest activity after storage, followed by Teno20 (Figure 3C).
[0177] Based on the above data, we proceeded to in vivo activity testing of Teno18 and Teno33 in human tenocytes and a mouse tendon injury model. To enhance in vivo cellular uptake, a cholesterol moiety was conjugated to the 3' end of the passenger strand of each compound (see, for example, Figure 1B for Teno18). Both Teno18 and Teno33 effectively knocked down col3a1 expression in human tenocytes (Figure 3D) and a mouse tendon injury model (Figure 3E). Treatment with Teno18 most effectively knocked down col3a1 expression in human tenocytes at day 5 (Figure 3D) and in a mouse tendon injury model at days 1 and 3 (Figure 3E).
[0178] Therefore, Tenol8 was selected as a clinical candidate for further in vivo studies, as described in the Examples below.
[0179] The drug substance (cholesterol conjugate Tenol 8, referred to as CWT-001) is synthesized using routine methods (solid-phase synthesis) and provided as a lyophilized powder. The drug product can be provided in a clear glass vial as a sterile solution containing 5 mg / mL of CWT-001, typically at pH 7.3, which is diluted with injectable saline prior to administration. Alternatively, CWT-001 can be provided as a sterile solution at a final concentration for administration (e.g., about 200 μg / ml, 500 μg / ml, 1500 μg / ml, 2000 μg / ml, 4500 μg / ml, or 5000 μg / ml, e.g., about 200 μg / ml, 500 μg / ml, 1500 μg / ml, or 4500 μg / ml). To optimize the stability of the drug substance, EDTA can be added, for example, to a final concentration of 0.001% to 0.005%, for example about 0.003% (100 μM).
[0180] Drug product vials can be stored and shipped at -20°C and are intended for single use. Frozen vials appear white and cloudy. Upon thawing to room temperature, the active pharmaceutical ingredient (API) solubilizes and becomes a clear, colorless solution.
[0181] The structure of the CWT-001 drug substance (as the sodium salt) is shown in Figure 1. Figure 1A shows the guide strand, and Figure 1B shows the passenger strand conjugated to a cholesterol moiety at the 3' end.
[0182] Example 2: In Vivo Primary Pharmacology Study (Figure 4) Because rodents have similar limb anatomy to humans, including tendons prone to tendinopathy (Achilles, patellar, and supraspinatus tendons) (12), a validated mouse tendon injury model was chosen to test whether treatment with CWT-001 significantly reduced collagen 3 expression and improved tendon healing. In these experiments, tendon injury was induced using a 0.75 mm diameter biopsy needle, followed immediately by injection of 0.35 μg / ml CWT-001 into the injury site. Mice were allowed to recover for 1, 3, or 7 days, and tendons were removed for histological and molecular analysis.
[0183] Treatment with CWT-001 significantly improved tendon fiber alignment and collagen production through suppression of collagen 3 expression in tendon disease (Figure 4A and Figure 4B).
[0184] Example 3: Secondary Pharmacology (Figures 5-7) Example 3a - Bioinformatics analysis of potential off-target effects of CWT-001 By their very nature, microRNAs interact with numerous target mRNA species, mostly through base pairing of a 6- to 8-nucleotide seed sequence. The sequence of the guide strand of CWT-001 is identical to that of native miR29a, meaning that CWT-001 targets the same mRNA as the native molecule via a RISC-dependent mechanism. To address the possibility of potential hybridization-dependent off-target effects, bioinformatics analysis of both the guide and passenger strands was performed as recommended by the Oligonucleotide Safety Working Group guidance (see Reference 13). This analysis generated a list of 52 genes, detailed below, that could theoretically hybridize with the guide and passenger strands of CWT-001. Mutations in 13 of these genes were associated with known human diseases, as detailed below.
[0185] A1) In silico assessment of potential hybridization-dependent propensity of the CWT-001 guide strand in precursor microRNA sequences Q-PCR analysis was performed on miRNA expression levels in primary human tenocytes after treatment with CWT-001. Potential cross-hybridization targets were identified as hsa-miR29a, hsa-miR29c, hsa-mir-1302-4, hsa-mir-3657, hsa-mir-3657, and hsa-mir-4647. The top hits in the sense (+) direction are the target microRNAs miR29a and miR29c (miR29b was not identified given the bioinformatics parameters used in this analysis). Potential cross-hybridization targets are in the complementary (-) direction. The top complementary microRNA sequences are the poorly characterized microRNAs hsa-mir-3657 and hsa-mir-4647. Both of these microRNAs may represent nonfunctional in silico artifacts. Furthermore, both of these sequences share a limited region of fully interrupted identity (10 bp) and are unlikely to have sufficient affinity to be strongly regulated by steric inhibition by miR29a mimics at physiological concentrations in vivo.
[0186] A2) In silico evaluation of potential hybridization-dependent trends of the CWT-001 guide strand in NCBI reference sequence (RefSeq) RNA sequences Q-PCR analysis was performed to assess the expression levels of potential off-target genes in primary human tenocytes after treatment with CWT-001. Potential cross-hybridization targets were identified as LAMA2, PDE7B, LRRC73, NETO1, FHL5, LINC00309, DOCK8, FILIP1, CUL9, CNOT8, LOC100132077, SCP2, and PROX2. Briefly, multiple unique genes were identified with 13–14 bp of continuous complementarity to the sequences in the complementary orientation suitable for cross-hybridization. No RNAs had more than 14 bp of continuous complementarity, limiting the possibility of cross-hybridization. Mutations in three genes (LAMA2, DOCK8, and SCP2) are associated with known human diseases.
[0187] B1) In silico assessment of potential hybridization-dependent propensity of CWT-001 passenger strands in precursor microRNA sequences qPCR analysis was performed on miRNA expression levels in primary human tenocytes after treatment with CWT-001. Potential cross-hybridization targets were identified as hsa-miR29a, hsa-mir-5186, hsa-mir-548at, hsa-mir-1283-2, hsa-mir-454, hsa-mir-4782, hsa-mir-515-1, hsamir-515-2, and hsa-mir-5691. The top complementary microRNA sequences are hsa-mir-548at, hsa-mir-1283-2, and the hsa-mir-515 family. All these sequences share limited regions of fully interrupted identity (11 bp or less) and are unlikely to have sufficient affinity to be strongly regulated by steric inhibition by CWT-001 at physiological concentrations in vivo.
[0188] B2) In silico assessment of potential hybridization-dependent propensity of CWT-001 passenger strands in NCBI reference sequence (RefSeq) RNA sequences qPCR analysis was performed to assess the expression levels of potential off-target genes in primary human tenocytes after treatment with CWT-001. Potential cross-hybridization targets were identified as PDCD10, ITGB6, LPGAT1, BPTF, CTTNBP2, EIF4A3, KIAA1210, SLC7A11-AS1, THSD4, TNFAIP3, ANKLE2, ARL4A, ATG14, BCL11A, CCDC83, CDH4, CLVS1, DKFZp434L192, ETV7, FBXO45, KCNJ1, LINC01973, MCF2L2, METTL5, NBN, POC1B, RAVER2, RPA2, ZNF441, ZNF667, and OPCML. Mutations in nine genes (ANKLE2, BCL11A, BPTF, EIFA3, ITGB6, KCNJ1, NBN, PDCD10, POC1B, & TNFAIP3) are associated with known human diseases.
[0189] C) Testing in human tendon cells To confirm whether any of the predicted potential interactions occurred, we measured the expression levels of potential off-target mRNAs in human tenocytes treated with 100 μg / ml CWT-001 for 24 hours using qPCR. Of the 52 potential off-target genes, only 12 were expressed in tenocytes, and of these, only four genes known to be associated with human disease (ANKLE2, SCP2, BPTF, and EIFA3) were expressed in tenocytes. Importantly, treatment with CWT-001 did not alter the expression of any of the genes highlighted as potential off-targets of CWT-001.
[0190] The data indicate that treatment with CWT-001 does not result in off-target effects in primary human tenocytes.
[0191] Example 3b - Immunogenicity evaluation of CWT-001 in primary human macrophages Double-stranded RNA (ds-RNA) can induce immune responses (Reference 14). To test whether CWT-001 could induce an immune response, cultured primary human macrophages, which are an important component of the innate immune system and sensitive to ds-RNA molecules, were treated with 0.35 μg / ml of CWT-001 for 24 hours (n = 4), and the levels of the proinflammatory cytokine tumor necrosis factor alpha (TNFα) were measured by ELISA. The results showed no induction of TNFα in CWT-001-treated cells (Figure 5).
[0192] qPCR analysis of an interferon-inducible gene panel (OAS2, INFα, IFTM1, MX1, IRF9, and OAS1) was additionally performed. Samples were normalized to 18S rRNA levels and expressed as fold change compared to untreated controls (n=3). qPCR analysis showed no change in expression in CWT-001-treated macrophages (Figure 6).
[0193] Taken together, these data indicate that CWT-001 does not induce immunogenicity in human macrophages.
[0194] Example 3c - Immunogenicity evaluation of CWT-001 in mice The immunogenicity of CWT-001 was tested in mice after CWT-001 injection into the patellar tendon. Animals were intratendinously injected with 50 μl of 0.35 μg / ml CWT-001 or PBS (n=3). Expression of known interferon-responsive genes, MX1, OAS2, IFITM1, and IRF9, was measured by qPCR on days 1, 3, and 7 and compared with the PBS control. The resulting data showed no increase in expression of interferon-responsive genes, suggesting that CWT-001 is non-immunogenic (FIG. 7). Indeed, the data suggest that CWT-001 has anti-inflammatory activity, as reflected by lower expression levels of interferon-responsive genes in mice treated with CWT-001 compared with the PBS control.
[0195] These data indicate that CWT-001 does not induce immunogenicity in a mouse tendon injury model and appears to have anti-inflammatory activity.
[0196] Example 4: Pharmacokinetics / Toxicokinetics (Figures 8-12) Example 4a - Detection of CWT-001 in preclinical models A two-step reverse transcription quantitative PCR (RT-QPCR) method for detecting CWT-001 in rat and dog RNA was validated. The assay was performed in the absence of matrix RNA at 10 8 ~10 3 The intra- and interassay accuracy and precision evaluation tests, performed by three analysts and seven times per matrix, demonstrated the robustness of the method within the established range.
[0197] An RNA QC pool sample for each matrix was prepared as an endogenous control to assess endogenous baseline levels. During sample analysis, the RNA QC pool sample was used for data normalization of the QC samples and to determine the expected Ct value and copy number. The RNA QC pool samples were set within the following values: -Ct 24.771~26.697 and / or 6.67E+03~3.31E+04 copies / reactive rat plasma - Ct 25.195~27.496 and / or 1.38E+03~2.79E+04 copies / reactive dog plasma - For rat tendons, Ct 23.284 to 24.352 and / or 5.45E+04 to 8.81E+04 copies / reaction -Ct 23.135~24.339 and / or 5.49E+04~9.88E+04 copies / reaction for canine tendons
[0198] The stability of CWT-001 in rat and dog spiked tendon samples stored in a freezer set to maintain -80°C was evaluated and showed stability for up to one month.
[0199] The methods used in these studies were considered suitable for the extraction and measurement of CWT-001 in rat and dog RNA.
[0200] Example 4b - Detectability and stability of CWT-001 in human serum Once CWT-001 entered the systemic circulation, the detectable period of CWT-001 relative to background levels of endogenous miR29a in human serum was measured. CWT-001 was diluted to a concentration equivalent to that expected immediately after intravenous (IV) delivery in adult humans (1:5,000 in 1 ml of serum, based on an average adult blood volume of 5 liters). Samples of 0, 2, 20, and 100 μg / ml CWT-001 were incubated with fresh human serum at 37°C for 0, 6, 12, and 24 hours. MiR29a levels were measured by qPCR, normalized to the Cel39 spike in control, and expressed as relative expression compared to untreated samples (n=3) (Figure 8). The increase in miR29a due to CWT-001 was only observed in purified samples less than 1 minute after addition of CWT-001, with miR29a levels returning to near untreated levels after 6 hours. This data indicates that CWT-001 is rapidly degraded to undetectable levels in human serum in vitro.
[0201] To further define the dynamics of CWT-001 in human serum samples, additional studies were conducted focusing on earlier time points (0, 15, 30, and 45 min; 1, 6, 12, and 24 h). MiR29a levels were measured by qPCR, and values were normalized to Cel39 spikes in the control and presented as relative fold changes compared to untreated samples (n = 3) (Figure 9). Data showed that CWT-001 levels increased to an average of 275-fold background levels when measured immediately after addition to serum, and declined to 61-fold background levels after 15 min. By 1 h, levels had declined to 11-fold background, and then declined to background levels at 12 h.
[0202] Example 4c - Pharmacokinetics and distribution of CWT-001 after IV administration To investigate the in vivo distribution of CWT-001 after intravenous injection, mice were injected with 50 μl of 50 mg / ml CWT-001, and serum, heart, liver, kidney, spleen, and muscle were collected on days 0, 1, 4, and 7. CWT-001 levels were measured using a miR29a qPCR assay, and values were normalized to GAPDH and presented as relative fold changes compared to untreated controls. Serum samples were normalized to Cel39 spiked in controls and presented as fold changes compared to untreated controls (n=4) (Figure 10). The data showed little or no increase in miR29a levels in serum or organs compared to saline controls. A slight increase in miR29a levels in the lungs was observed on day 1, which returned to baseline by day 4.
[0203] These data indicate that CWT-001 has negligible distribution in tissues after intravenous administration, even when administered at 25 times the typical clinical dose level (i.e., 25 times 2 mg / m2 in 50 μl, which is the mouse equivalent of the human clinical dose of 1 ml of 2 mg / ml CWT-001).
[0204] Example 4d - Systemic exposure of CWT-001 in the circulation after intratendinous injection Measurements of systemic exposure to CWT-001 were performed in mice injected into the patellar tendon with 25 μl of 2 mg / ml CWT-001 or PBS control (n=4 per group), and blood was collected at 0, 15, 30 min, 1, 2, 4, 6, 24, and 72 h. CWT-001 levels were measured using the miR29a qPCR assay, and values were normalized to Cel39 spike in control and expressed as fold change relative to the PBS control (n=4).
[0205] After intratendinous administration, increases in blood miR29a levels were observed 2 and 4 hours after injection. miR29a levels returned to background levels by 6 hours (Figure 11). This data suggests that while CWT-001 enters the circulation after intratendinous injection, it is rapidly cleared, likely due to degradation by serum nucleases and excretion by the kidney. The absolute levels of endogenous miR29a observed throughout the body are very low (compared to concentrations present in cells, for example). Therefore, the 5- to 14-fold relative increase in systemic miR29a levels observed 2 and 4 hours after CWT-001 injection (Figure 11) still translates into very low absolute systemic miR29a levels. Furthermore, as noted above, the majority of serum CWT-001 is rapidly cleared. Less than 1% of CWT-001 is ultimately taken up by cells via the serum. Overall, this means that only very low absolute levels of administered CWT-001 enter non-target cells upon systemic exposure. The observed systemic increase in CWT-001 is therefore unlikely to have any pharmacodynamic effects in cells other than target cells within the tissue (e.g., tendon) into which CWT-001 is administered.
[0206] This data indicates that CWT-001 has limited systemic distribution after intratendinous injection.
[0207] Example 4e - Distribution of CWT-001 after intratendinous administration To understand the tissue distribution of CWT-001 after intratendinous injection, mice were injected with 50 μl of 4, 20, 40, and 50 mg / ml CWT-001 or PBS control into the patellar tendons. Organs and peripheral blood were collected 7 days later. CWT-001 levels were measured using a miR29a qPCR assay, and values were normalized to GAPDH and presented as relative fold changes compared to untreated controls. Serum samples were normalized to Cel39 spiked in controls and presented as fold changes compared to placebo (n=4). The resulting data (Figure 12) did not demonstrate a significant increase in miR29a levels in any organ at any concentration compared to placebo. A trend toward significance was observed in the spleen at the two highest doses, which were higher than any typical equivalent human clinical dose.
[0208] These data indicate that CWT-001 has negligible tissue distribution, even at the highest doses, which are up to 25-fold the highest typical human clinical equivalent dose.
[0209] Example 4f - Toxicokinetics in rats after intratendinous administration in a single-dose toxicity study Toxicokinetic evaluation was incorporated into the design of a single-dose toxicity study of CWT-001 by intratendinous injection in rats with a 14-day recovery period (Example 5c).
[0210] Rats were treated with a 30 μL injection of saline control, 10 mg / ml, or 50 mg / ml CWT-001 (i.e., a total dose of 0, 0.3, or 1.5 mg). Blood samples were collected from the jugular vein of three animals per sex per group at 0.5, 1, 2, 4, 8, and 24 hours post-dose, and plasma was prepared. Plasma samples were analyzed for CWT-001 concentrations using a validated analytical tool (RT-QPCR).
[0211] Toxicokinetic parameters were estimated using a non-compartmental approach consistent with the intratendinous route of administration in this study. A summary of the toxicokinetic parameters is shown in Table 2 below. [Table 7] The plasma CWT-001 concentration versus time profile showed a rapid absorption phase (T max (The mean plasma CWT-001 concentration was 0.5 h for all profiles.) Plasma CWT-001 concentrations declined in a multistep fashion until 4 h after dosing, after which in females, concentrations increased slightly until 8 h (final quantifiable concentration, 0.3 mg) or remained relatively constant until the end of the 24-h sampling period (1.5 mg). In males, concentrations at both doses remained constant until 4 h after dosing, until the end of the 24-h sampling period. With increasing dose from 0.3 mg to 1.5 mg, systemic exposure to CWT-001 generally increased less than dose-proportionally in females and more than dose-proportionally in males. Systemic exposure to CWT-001 was higher in males than in females at both the 0.3 mg and 1.5 mg dose levels.
[0212] Example 4g - Toxicokinetics in dogs after intratendinous administration in a single dose toxicity study Toxicokinetic evaluation was incorporated into the design of a single-dose toxicity study of CWT-001 by intratendinous injection in dogs with a 14-day recovery period (Example 5d).
[0213] Dogs were treated with 250 μL injections of saline control, 10 mg / ml, or 50 mg / ml CWT-001 (i.e., total doses of 0, 2.5, or 12.5 mg). Blood samples were collected from the jugular vein of three animals per sex per group at 0.5, 1, 2, 4, 6, and 48 hours post-dose, and plasma was prepared. Plasma samples were analyzed for CWT-001 concentrations using a validated analytical tool (RT-QPCR).
[0214] Toxicokinetic parameters were estimated using a non-compartmental approach consistent with the intratendinous route of administration in this study. A summary of the toxicokinetic parameters is provided below. [Table 8]
[0215] Plasma CWT-001 concentration versus time profiles showed a rapid absorption phase (T = 0.5 or 1 hour). max This was followed by a biphasic decrease in concentrations, initially rapid until 1 or 2 hours after dosing, and then at a slower rate until final quantifiable concentrations (except in females receiving 12.5 mg, which showed a slight increase in concentrations 4 to 6 hours after dosing). As the dose increased from 2.5 mg to 12.5 mg, systemic exposure to CWT-001 generally increased more than dose-proportionally in females and less than dose-proportionally in males. Systemic exposure to CWT-001 was greater in males than in females at the 2.5 mg dose level, but was comparable between the sexes at 12.5 mg.
[0216] Example 5: Toxicology Example 5a - Tolerance study of CWT-001 by single intratendinous injection in rats The purpose of this study was to determine the potential toxicity of CWT-001 when administered to rats via intratendinous injection, with the goal of establishing and confirming the maximum feasible dose (MFD). The study design is shown in Table 4 below. [Table 9]
[0217] Each animal received a single intratendinous injection (30 μL) of CWT-001 into the right Achilles tendon using a 0.5 mL insulin syringe. The animals were anesthetized using isoflurane, and the tendon was exposed using a small surgical incision in the hind limb to allow placement of CWT-001. After administration of the dose, the animals were sutured closed.
[0218] The highest dose level (1.5 mg) represents the maximum feasible dose that can be administered by this route, limited by the solubility of the test article and the volume that can reasonably be injected into the tendon. The following parameters and endpoints were evaluated in this study: clinical observations, body weight, and gross necropsy findings. No clinical signs, body weight changes, or gross necropsy findings were considered related to CWT-001.
[0219] In conclusion, single intratendinous administration of CWT-001 up to 1.5 mg was well tolerated in HanWistar rats, with no clinical, body weight, or gross necropsy findings observed.
[0220] Example 5b - Tolerance study of CWT-001 in dogs via a single intratendinous injection The objective of this study was to determine the potential toxicity of CWT-001 following a single intratendinous injection in dogs and to provide data to support the selection of dose levels for a subsequent 14-day toxicity study. The study design is shown in Table 5 below. [Table 10]
[0221] Each animal received a single intratendinous injection (250 μL) of CWT-001 into the right Achilles tendon using a syringe. The animals were anesthetized using isoflurane, and the tendon was exposed using a small surgical incision in the hind limb to allow for placement of CWT-001. After administration of the dose, the animals were sutured closed.
[0222] The dose level used (12.5 mg) represents the maximum feasible dose that can be administered by this route, limited by the solubility of the test article and the volume that can reasonably be injected into the tendon. The following parameters and endpoints were evaluated in this study: clinical observations, body weight, food intake, clinical pathology parameters (hematology, coagulation, and clinical chemistry), gross necropsy findings, and organ weights.
[0223] There were no clinical observations associated with CWT-001, nor were there any changes in body weight, food intake, hematology, coagulation, or clinical chemistry parameters. Furthermore, there were no changes in gross necropsy findings or organ weights that were considered to be related to CWT-001. In conclusion, administration of CWT-001 at a single intratendinous dose of 12.5 mg in beagle dogs was well tolerated, with no clinical observations, no changes in body weight, food intake, or clinical pathology parameters, and no changes in gross pathology or organ weight findings.
[0224] Example 5c - Single-dose toxicity study of CWT-001 by intratendinous injection in rats with a 14-day recovery period The objective of this study was to determine the potential toxicity of CWT-001 following a single intratendinous injection in rats and to evaluate the potential reversibility of any findings over a 14-day recovery period following injection. Additionally, the toxicokinetic properties of CWT-001 were determined. The study design is shown in Table 6 below. [Table 11] The following parameters and endpoints were evaluated in this study: clinical observations, body weight, food consumption, ophthalmology, behavioral observations (Irwin score), respirometry, clinical pathology parameters (hematology, coagulation, clinical chemistry, and urinalysis), bioanalytical and toxicokinetic parameters, gross necropsy findings, organ weights, and histopathological examination.
[0225] The highest dose level (1.5 mg) represents the maximum feasible dose that can be administered by this route, limited by the solubility of the test article and the volume that can reasonably be injected into rat tendons (see Example 5a). All formulation analysis results were found to be within the acceptance criteria of 10% of the theoretical concentration (individual values within 15%).
[0226] There were no unexpected deaths during the course of the study. There were no clinical signs, body weight and food consumption, ophthalmoscopic findings, changes in behavioral observations, changes in respiratory parameters, changes in organ weights, gross findings, or histopathological findings that were considered related to CWT-001. At 0.3 mg or 1.5 mg, there was a slight but dose-dependent decrease in red blood cell mass (red blood cells, hematocrit, and hemoglobin) and an increase in reticulocytes on day 3 in both males and females. All changes showed resolution by day 15.
[0227] In conclusion, administration of CWT-001 by a single intratendinous injection up to 1.5 mg was well tolerated in Han Wistar rats and was associated with a transient slight decrease in red blood cell mass and an increase in reticulocytes on day 3, which showed recovery by day 15. There were no other in-vivo or any histopathological findings associated with CWT-001.
[0228] Based on the results of this study, which administered the maximum feasible dose, 1.5 mg of CWT-001 was considered to be the no observed adverse effect level (NOAEL) in rats.
[0229] Example 5d - Single-dose toxicity study of CWT-001 by intratendinous injection in dogs with a 14-day recovery period
[0230] The objective of this study was to determine the potential toxicity of CWT-001 following a single intratendinous injection in dogs and to assess the potential reversibility of any findings. Additionally, the toxicokinetic properties of CWT-001 were determined.
[0231] Each animal received a single dose of CWT-001, with the main study animals being euthanized on day 3 and the recovery animals being euthanized on day 15. The study design is shown in Table 7 below. [Table 12] The following parameters and endpoints were evaluated in this study: clinical observations, body weight, food intake, ophthalmology, cardiovascular data, clinical pathology parameters (hematology, coagulation, clinical chemistry, and urinalysis), bioanalysis (plasma and tendon) and toxicokinetic parameters, gross necropsy findings, organ weights, and histopathology.
[0232] The highest dose level (12.5 mg) represents the maximum feasible dose that can be administered by this route, limited by the solubility of the test article and the volume that can reasonably be injected into a dog's tendon (see Example 5b). All formulation analytical results were found to be within the acceptance criteria of 10% of the theoretical concentration (individual values within 15%).
[0233] There were no unexpected deaths during the course of the study. There were no clinical signs, changes in body weight or food consumption, ophthalmoscopic findings, electrocardiographic findings, clinical pathology findings (hematology, coagulation, clinical chemistry, and urinalysis), changes in organ weight, or gross or histopathological findings that were considered to be related to CWT-001.
[0234] In conclusion, single intratendinous administration of CWT-001 up to 12.5 mg was well tolerated in beagle dogs and was associated with only treatment-related findings. There were no in-life or histopathological findings related to CWT-001. Based on the results of this study using the maximum feasible dose, 12.5 mg of CWT-001 was considered to be the no-observed-adverse-effect level (NOAEL) in dogs.
[0235] Example 6: Safety Pharmacology Safety pharmacology endpoints were incorporated into the design of single-dose toxicity studies in rats and dogs (Examples 5c and 5d, respectively) to assess central nervous system, respiratory, and cardiovascular effects.
[0236] Example 6a - Central Nervous System in the Rat (Modified Irwin Observations) The first six male main test animals from each group were observed at 2, 24 and 48 hours post-dose. The following parameters were included in the observations: -Occurrence of vocalization, stereotypic behavior, aggression, abnormal gait, straub tail, tremors, convulsions, spasms, posturing, sedation, catalepsy, ptosis, exophthalmos, salivation, lacrimation, piloerection, abnormal breathing, defecation, urination, and death. -Increase or decrease in spontaneous activity, touch response, body tone and pupil size. Increased sniffing, grooming, scratching, and rearing. - Decreased pinna reflex, abnormal pulling response, and abnormal grip strength. Any additional symptoms observed were recorded. The frequency of animals showing symptoms and the severity of symptoms were recorded. Pupil size: Measured using a guidance chart to estimate size in millimeters (pre-dose pupil size data was recorded on the day of dosing). - Body temperature: Measured using a probe inserted approximately 2 cm from the anal sphincter. Pre-dose body temperature was also recorded. To reduce variability in measurements, a temperature acclimation trial was performed by inserting a temperature probe before recording pre-dose measurements, but body temperature data were not collected during this trial.
[0237] No findings considered related to CWT-001 administration were observed during the modified Irwin observations. Although a decrease in grip strength was occasionally observed in some animals at some time points, these findings were also observed in the control group at a single time point and are therefore considered unrelated to CWT-001 administration. There were no changes in pupil size or body temperature associated with CWT-001 administration.
[0238] Example 6b - Respiration measurements in rats On the day of testing, animals were removed from their home cages and placed in the whole-body plethysmograph chamber for approximately 45 minutes, with the last 15 minutes of this period designated as the control period. Animals were then removed from the chamber for administration of the control or test article. Measurements were then taken 2-4 hours, 24 hours, and 51 hours after administration, with animals remaining in the chamber for at least 30 minutes of acclimation before any measurements. The effects of chamber temperature and humidity on tidal volume were corrected within the plethysmograph chamber. Ventilation parameters were determined from the respiratory signal. The sampling frequency was fixed at 500 Hz.
[0239] No changes in respiratory parameters were considered to be related to administration of CWT-001. Occasional statistically significant variations in respiratory parameters were present sporadically during the study, but these were considered to be due to control group variations at specific time points or to minimal and / or transient changes and therefore unrelated to administration of CWT-001.
[0240] Example 6c - Cardiovascular evaluation in dogs Cardiovascular assessments were performed at least 26 hours before treatment (before Day 1), at least 20 hours after treatment on Day 2 (data acquisition 24–44 hours after treatment), and on Day 14 during the recovery period. Each animal's ECG and blood pressure were recorded using a Jacketed External Telemetry (JET™) system combined with a PA-C10-TOX-LA transmitter (Data Sciences International (DSI™), St. Pauls, MN, USA). Before the first recording session, all animals were acclimated to the JET jacket and individually observed to ensure they tolerated the procedure. On the day of data acquisition, animals were removed from their home enclosures and taken to the procedure room for placement of ECG leads and attachment of the jacket (and collar, if necessary). The areas required for electrode placement were shaved and appropriately prepared. Arterial blood pressure, heart rate, and lead II ECG variables were continuously acquired using a 1-minute logging rate. ECG and blood pressure were recorded before treatment and during recovery. Recordings were conducted for at least 26 hours. On Day 2, ECG and BP recordings were conducted for at least 20 hours (data acquired 24-44 hours post-dose) (T=0 corresponds to the end of test article administration). Animals were not restrained except when treatment was administered. At least 26 hours of pre-treatment telemetry data acquisition was recorded from all animals prior to the start of the study dosing phase. Sections of these pre-treatment signals were examined for ECG morphology abnormalities, signal quality, heart rate, arterial blood pressure, and normality of ECG values (including QTca calculation [QT corrected for heart rate]), as appropriate.
[0241] The following parameters were reported: · Systolic blood pressure (SBP), diastolic blood pressure (DBP), and mean arterial blood pressure (MAP), and heart rate (HR) derived from the blood pressure waveform. ECG parameters (corrected RR, PR, QRS, QT, QTca, and QA intervals [derived from blood pressure and ECG waveforms] for each individual animal) were analyzed. Any observed lead II ECG abnormalities or arrhythmias were printed and reviewed.
[0242] No changes in cardiovascular parameters or waveform morphology were considered to be related to administration of CWT-001 throughout the course of the study. Occasional or transient findings in individual animals were not considered to be related to the test article because they were also observed in control animals or were considered to be due to normal animal-to-animal variability.
[0243] Example 6d - Reproductive and Developmental Toxicity Single-dose toxicity studies in rats and dogs did not reveal any treatment-related organ weight and histopathological changes in reproductive organs, including the testes and ovaries.
[0244] Example 6e - Local Tolerance Local tolerance has been assessed in single-dose toxicity studies in both rats and dogs, which did not reveal any unexpected effects at the injection site.
[0245] Example 7: Administration to human subjects with lateral epicondylitis (Figures 13 and 14) The results from the above examples demonstrate that the miR-29 compounds provided herein are safe and effective in reducing or inhibiting collagen 3 expression in vivo, including in mouse models of tendinopathy. Furthermore, we previously demonstrated that the equine collagenase-induced tendinopathy (SDFT) model mirrors human tendinopathy, with decreased miR-29a expression and a concomitant increase in the Col3:Col1 ratio after tendon injury. A single intralesional injection of miR-29 compounds (100 nM, approximately 2 μg / ml in a total volume of 1.5 ml, i.e., a total dose of 3 μg) reduced collagen 3 expression and lesion size and improved tendon structure (see Reference 3). Collectively, these data provide a rationale for safe and effective human therapies using miR-29 compounds, including those provided herein.
[0246] A Phase 1, randomized, double-blind, placebo-controlled study was conducted to evaluate the safety, tolerability, and pharmacokinetics of single ascending doses of CWT-001 injections in subjects with lateral epicondylitis (see Figure 13 for study design).
[0247] The current second-line (after physical therapy) standard for curative treatment of lateral epicondylitis remains local injection of corticosteroids into the area of tendon pain, although the long-term benefit remains questionable. Local injection of CWT-001 into the area of tendon injury at the origin of the common extensor tendon at the elbow thus maintains the current standard of care but exhibits improved safety and efficacy. Ultrasound-guided injection into the area of tendon injury is used, as ultrasound is often used as the imaging modality of choice not only to assess tendon status but also to guide injection therapy (15).
[0248] The primary objective of this study is to determine the safety and tolerability of single ascending doses of CWT-001 in human subjects with lateral epicondylitis.
[0249] The secondary objectives of this study are to determine the single-dose pharmacokinetics (PK) of CWT-001 administration in human subjects with lateral epicondylitis and to evaluate the efficacy of CWT-001 administration in human subjects with lateral epicondylitis.
[0250] The primary endpoint of the study is a comparison of safety data between CWT-001 and placebo, as measured by the incidence of adverse events (AEs), clinical laboratory abnormalities, changes in vital signs (blood pressure, temperature, respiratory rate, pulse rate), 12-lead electrocardiogram (ECG) parameters, physical examination, and skin score assessment 14 days after injection.
[0251] Secondary endpoints of this study were: -Maximum plasma concentration (C max ), C max Time to (t max ), plasma PK concentration of the data, shown by the area under the plasma versus concentration-time curve (AUC). - The efficacy of a single dose of CWT-001 on elbow pain as measured using a visual analog scale (VAS) at baseline, Days 1-14, 28, and 90. - The efficacy of a single dose of CWT-001 on disability and symptoms as measured using the DASH (Disabilities of the Arm, Shoulder, and Hand) score at Days 1-14, 28, and 90 prior to dosing. - The efficacy of a single dose of CWT-001 on pain and disability as measured by Patient Rated Tennis Elbow Evaluation (PRTEE) at baseline, Days 1-14, 28, and 90. - The efficacy of a single dose of CWT-001 on the lateral elbow tendon as measured by change from baseline ultrasound assessment at Days 1-28 and 90 prior to dosing.
[0252] Dosage basis Considering the experiments described above, miR-29 doses in the μg and low mg range are expected to be effective and well-tolerated in animal species and can be administered in volumes that are easily and safely injectable (e.g., approximately 1 ml). These dose levels also support a collagen-targeting mechanism of action, for example, in improving tendon healing in the animal models used. Single-dose extended toxicity studies via intratendinous administration were conducted in rats (up to 1.5 mg, see Example 5a) and dogs (up to 12.5 mg, see Example 5b), with the no-observed-toxicity level in each study being the maximum feasible dose. Preclinical evaluation of single intratendinous administration of CWT-001 produced no adverse findings at doses 41-fold and 25-fold higher in rats and dogs, respectively, compared to, for example, the human clinical dose of 2 mg.
[0253] Subjects were divided into cohorts (8 subjects per cohort) and randomized to receive a single 1 ml dose of CWT-001 (a 5 mg / mL solution of CWT-001 in PBS and EDTA diluted to various final concentrations using saline, i.e., 0.9% w / v NaCl) or matching placebo (saline, i.e., 0.9% w / v NaCl) (3:1) administered by intratendinous injection. The starting dose of CWT-001 was 200 μg / mL. The dose was gradually increased to 500 μg / mL and then 1500 μg / mL. If no improvement in VAS pain ratings was observed, an additional dose of (up to) 4500 μg / mL was planned to be administered, but this was not necessary.
[0254] In each cohort, no more than two subjects (one active, one placebo) were dosed on the first dosing day, such that no more than one subject received the first active CWT-001 dose at each dose level. After evaluation of safety and tolerability in the previously dosed sentinel subjects, dosing continued in the remaining subjects (6 subjects, 5 active, 1 placebo) at the same dose level in each cohort.
[0255] Doses were administered in an escalating fashion from lower doses after satisfactory review of all safety, tolerability, plasma PK, and efficacy data (when available). Doses were determined based on ongoing evaluation of safety, tolerability, plasma PK, and efficacy data (when available). All doses were given as 1 ml injections under ultrasound guidance into the affected area.
[0256] Ultrasound examination was performed using a 5-7.5 MHz linear array transducer on a LOGIQ E9 ultrasound system. The probe was placed along the lateral side of the elbow parallel to the longitudinal axis of the common extensor tendon. The radial head, radiohumeral joint, lateral epicondyle, and common extensor tendon were visualized. The skin was sterilized, and the USG probe was placed in a sterile cover. After visualization of the needle tip at the correct site (low intensity area), 1 mL of CWT-001 or placebo was injected (see Figure 14).
[0257] CWT-001 was administered to the tendon using the "pep method" (Reference 11). The "pep method" is an injection method whereby a needle is inserted into the tendon area, and then multiple small injections are given by withdrawing, reorienting, and reinserting the needle without it ever leaving the skin. In the setting of injured / chronic tendons, this may be preferable to stimulate a healing response.
[0258] The study population included 24 subjects, each of whom met all inclusion criteria and none of the exclusion criteria for the study.
[0259] Subjects met the following criteria for inclusion in the study: 1. Subjects may be male or female, of any racial origin. 2. The subjects were between 18 and 70 years old, and there was no evidence of skeletal immaturity. 3. The target is 18-35 kg / m 2 have a body mass index (BMI) of 4. The subject weighs 50 kg or more. 5. Subject has a clinical diagnosis of lateral epicondylitis. 6. With the exception of lateral epicondylitis and any conditions listed in the exclusion criteria below, subjects are otherwise healthy as determined by the investigator based on medical history, physical examination, concomitant medications, vital signs, 12-lead ECG, and clinical laboratory evaluation. Laboratory values may be retested once at the investigator's discretion. 7. Subject's symptoms can be reproduced with resisted supination or dorsiflexion of the wrist (confirmed by tenderness over the lateral epicondyle and the sign of rear chair lift). 8. Subject's symptoms have persisted for at least 6 weeks to 6 months despite conservative treatment, including one or a combination of the following: a.Physical therapy b. Splinting c. NSAIDs 9. Subject is independent, ambulatory, and able to comply with all post-injection evaluations and visits. 10. Male subjects with female partners of childbearing potential must use condoms throughout the study and for 3 months after the final dose of study drug. In addition, their female partners of childbearing potential must use an additional method of highly effective contraception (a method that, when used consistently and correctly, can achieve a failure rate of less than 1% per year is considered highly effective) from 1 month before dosing until 3 months after dosing. 11. Female subjects of childbearing potential must agree to use highly effective contraception for 1 month prior to dosing, in combination with condom use by the male partner, throughout the study and for 3 months after dosing. Subjects must have a negative pregnancy test at screening and on Day 1. 12. Provision of written informed consent, including compliance with the requirements and restrictions listed in the consent form.
[0260] Subjects were excluded from participation in this study if they met any of the following criteria: 1. Subjects have received corticosteroid injection therapy in the affected elbow within 6 months prior to enrollment. 2. Subject is unwilling or unable to discontinue use of analgesics (opiates or NSAIDs) from at least 1 week prior to IMP administration. 3. Subject has previously received a PRP injection into the affected elbow. 4. Subject is currently using or has recently used medications known to affect the skeleton (e.g., glucocorticoid use >5 mg / day, fluoroquinolone antibiotics). 5. Subject has had a surgical intervention on the affected elbow for the treatment of lateral epicondylitis. 6. Subject has a positive medical history of any of the following: a. Medial epicondylitis b.Radial tunnel syndrome C. Carpal tunnel syndrome d. Septic or gouty arthritis in the affected elbow within the past 2 years prior to enrollment e. Cervical radiculopathy within 6 months prior to enrollment f. Trauma to the affected elbow within the past 6 weeks g. Neuromuscular or primary / secondary muscle deficits that limit the ability to perform functional measurements (e.g., grip strength testing) h. Occasional rheumatic inflammatory diseases, including but not limited to axial spondyloarthritis, psoriatic arthritis, and rheumatoid arthritis i. Osteoarthritis of the affected elbow j. Fibromyalgia judged to be sufficient to impair response assessment 7. Subject currently has an acute infection at the injection site. 8. History of lymphoproliferative disorder or known malignancy, treated or untreated within the past 5 years prior to baseline with or without evidence of local recurrence or metastasis, or history of malignancy of any organ system (excluding basal cell carcinoma, squamous cell carcinoma, or actinic keratosis of the skin, cervical intraepithelial carcinoma, or resected noninvasive malignant colon polyp that has been treated without evidence of recurrence within the past 5 years). 9. Subject is physically or mentally impaired to the extent that, in the judgment of the investigator, they are unable or unlikely to maintain compliance (e.g., currently receiving treatment for psychiatric disorders, senile dementia, Alzheimer's disease, etc.). 10. Subject has received an investigational therapy or a therapy approved for investigational use within 30 days of the injection procedure or during the follow-up phase of the study.
[0261] Subjects must refrain from strenuous exercise for 48 hours prior to each visit and while in the CRU. Subjects are also not permitted to drive any motor vehicle for at least 24 hours after injection of the investigational drug (IMP).
[0262] Subjects were required to adhere to the following restrictions:
[0263] Subjects must abstain from alcohol for 48 hours prior to each visit until discharge from the Clinical Research Unit (CRU). Subjects must abstain from tobacco and nicotine-containing products (including e-cigarettes) for 90 days prior to dosing and throughout the study period until the end of the study. Subjects must refrain from consuming poppy seeds for 48 hours prior to screening and each visit to avoid a positive result on the substance abuse screen.
[0264] Subjects fasted overnight for 8 hours prior to dosing. Additionally, subjects are encouraged to fast for at least 4 hours prior to any clinic visit where clinical laboratory evaluations are performed.
[0265] Screening ultrasound assessments were performed at any time during the 4-week screening period and included a scan of the contralateral elbow. At least 1 week prior to dosing, subjects were asked to discontinue any opiate or NSAID medications they were using for pain management. From day -7 to day -1, subjects were allowed to take paracetamol (up to 4 g / day) or use ice packs to manage pain.
[0266] Subjects were admitted to the CRU on Days -2 / -1 and prior to dosing on Day 1 to confirm eligibility and undergo baseline safety and efficacy assessments. After confirmation of eligibility, subjects were randomized and received CWT-001 or placebo. After injection, subjects rested for 30 minutes. Subjects underwent post-dose safety and PK assessments and were discharged from the CRU the same day. Subjects returned to the CRU on Day 2 for PK sampling assessments and on Day 7 for safety and PK assessments. Subjects returned to the CRU on Days 14, 28, and 90 for safety and efficacy assessments (further details are provided below). Subjects underwent ultrasound assessments on Days 28 and 90. The study duration for each subject is approximately 16 weeks.
[0267] The impact of tendinopathy on various aspects of patients' health-related quality of life was assessed using the following instruments, which are accepted and validated as patient-reported outcome tools in upper extremity tendinopathy (Ref. 16): subject's assessment of tendinopathy pain intensity (VAS), QuickDASH score, ASES-E score, PRTEE score, and ultrasound assessment of the tendons at 28 and 90 days after injection.
[0268] Discontinuation criteria included: - A "serious" adverse reaction in one subject, i.e., a serious adverse event (SAE, as defined below) that was at least probably related to IMP administration. "Severe" non-serious adverse reaction, i.e., a severe non-serious AE that is at least probably related to IMP administration in two subjects in the same cohort, whether or not within the same System Organ Class (SOC). -If there is an unacceptable tolerability profile based on the nature, frequency, intensity of observed AEs and / or clinical safety monitoring.
[0269] An AE is any undesired medical occurrence in a study subject that emerges from screening or worsens during a clinical trial, regardless of its potential relationship to the drug. An AE can therefore be any untoward or unintended manifestation, including a clinically significant abnormal laboratory finding, symptom, or disease.
[0270] An SAE is any untoward medical occurrence at any dose that: resulting in death, Life-threatening. -Note: The term "life-threatening" in the definition of "serious" refers to an event that puts the subject at risk of death at the time of the event. It does not refer to a hypothetical event that, if more severe, might have resulted in death. ·requires hospitalization or extension of an existing hospitalization; -Note: Generally, hospitalization means that a subject has been detained in a hospital or emergency room (usually involving at least an overnight stay) for observation and / or treatment that would not have been appropriate in a physician's office or outpatient setting. A complication that occurs during hospitalization is an AE. If the complication prolongs the hospital stay or meets any other serious criteria, the event is serious. An AE should be considered serious if there is any doubt as to whether "hospitalization" occurred or was necessary. · Causes permanent or serious disability or incapacity. -Note: The term "incapacitating" means that a person's ability to perform the functions of daily living is significantly impaired. This definition is not intended to include experiences of relatively minor medical significance, such as simple headache, nausea, vomiting, diarrhea, or the flu, and accidental injuries (such as a sprained ankle) that may interfere with or hinder daily living functions but do not result in substantial disruption. · You have a birth abnormality or birth defect. · It is a significant medical event. -Note: Medical or scientific judgment should be used in determining whether reporting is appropriate in other situations, such as significant medical events that are not immediately life-threatening or do not result in death or hospitalization, but which may endanger the subject or require medical or surgical intervention to prevent one of the other outcomes listed in the definition above. These should also be considered serious. Examples of such events are invasive or malignant cancer, allergic bronchospasm that does not result in hospitalization, intensive care in the emergency room or at home for blood disorders or seizures, and the development of drug addiction or substance abuse. -Note: The terms "serious" and "severe" are not synonymous. The term "severe" is often used to describe the intensity (severity) of a particular event (e.g., mild, moderate, or severe myocardial infarction); however, the event itself may be of relatively less serious medical significance (e.g., severe headache). This is not the same as "serious," which is based on the subject / event outcome or behavior criteria described above and typically relates to an event that threatens the life or function of the subject. A severe AE does not necessarily have to be considered serious. For example, nausea that lasts for several hours may be considered severe nausea but is not an SAE. On the other hand, a stroke that results in only mild incapacity may be considered mild but is defined as an SAE based on the criteria described above. Severity (rather than severity) serves as a guide for defining regulatory reporting obligations
[0271] No subjects met any of the discontinuation criteria during the study.
[0272] Pharmacokinetic evaluation The pharmacokinetics of CWT-001 was assessed by measuring serial plasma concentrations of miR29a.
[0273] Baseline PK blood samples were collected within 30 minutes prior to dosing. Blood samples for measuring miR29a plasma concentrations were collected at the time points listed in Table 9 below. Plasma concentration-time data were analyzed by non-compartmental methods. Nominal times were used for interim determinations, but actual sampling times were used for final calculations. Approximate sampling volumes are shown in Table 8. [Table 13]
[0274] Additional samples were taken if necessary for safety reasons. Up to two additional pharmacokinetic samples may be taken as needed to define the pharmacokinetic profile.
[0275] Pharmacokinetic plasma samples were collected and miR29a was quantified using a validated quantitative real-time PCR method developed at ThermoFisher. [Table 14] TIFF2023547274000028.tif46162
[0276] Efficacy Assessment - Visual Analogue Scale Subjects rated their pain in a daily diary for the first 14 days after treatment, scoring pain over the past 24 hours. From day 14 onward, subjects kept weekly pain diaries until day 90 after injection. Subject pain assessments were conducted using a 100-mm visual analog scale (VAS) ranging from "no pain" to "unbearable pain" after the question, "Please indicate the worst pain from tendinopathy during the last 24 hours using a vertical line (|) on the horizontal line." The VAS is a validated instrument that attempts to measure characteristics or attitudes that are thought to span a continuum of values and cannot be easily measured directly. It is often used in epidemiological or clinical studies to measure the intensity or frequency of various symptoms (17).
[0277] The results are shown in Figure 17. Reductions in VAS scores were observed in all groups of subjects receiving 200 μg (Figure 17A), 500 μg (Figure 17B), or 1500 μg (Figure 17C) of CWT-001, as well as in subjects receiving placebo saline injections. These VAS score reductions generally exceeded the minimal clinically important difference (MCID) of -11 for VAS in the treatment of elbow pain (Reference 18). The mean change in VAS score for all subjects receiving any dose of CWT-001 was determined and compared with placebo (Figure 17D). Treatment with CWT-001 resulted in a change in VAS score that exceeded that observed with placebo at 28 days. The observed mean change in VAS score was -33 ± 7 for CWT-001-treated subjects at 90 days, corresponding to a change of 3 MCIDs.
[0278] Randomized controlled trials (RCTs) in orthopedic surgery evaluate the use of saline (NS) injections as a placebo / control group, anticipating the substance's nonphysiological effects. However, as suggested by the current best evidence in this field (Refs. 18, 19, 20, 21), questions arise as to whether NS can act as an appropriate placebo in this field. For example, a recent study of intra-articular injections of saline into the knee joints of patients with osteoarthritis (Ref. 22) suggested impressive and potentially beneficial effects of saline, such as pain relief and osmolality-related changes. From a molecular and physiological perspective, the contribution of hypertonic saline administration in reducing proinflammatory cytokines (RANTES, MCP-1, IP-10, G-CSF) following induction by TNF-α and IL-1b, as well as how sodium ions and osmolality may contribute to the pathology of osteoarthritis, suggest that it is a potent anti-inflammatory mediator. Clinical trials of tendinopathy in which intratendinous saline injections were used as a control showed a placebo effect of 70% reduction in VAS scores (18).
[0279] A recent systematic review of NS as a placebo, particularly in lateral epicondylitis trials (Ref. 23), found no statistically significant differences in patient-reported outcome measures (PROMS) between saline and non-saline injections (platelet-rich plasma (PRP), autologous adjusted plasma (ACP), corticosteroids, and botulinum toxin) in all but one RCT reviewed, suggesting that NS exerts similar therapeutic effects to the injection therapies tested. Based on this study, and in the absence of solid evidence to elucidate the principles, physiological characteristics, effects, and underlying mechanisms of NS injections, it has been suggested in the field that alternative control methods, such as sham syringes / needles, may serve as better control arms in trials (Boesen et al., 2017; see references such as those described in references).
[0280] Given the known issues associated with the use of intratendinous saline injections as a placebo in tendinopathy studies, the mean percent change in VAS score for all subjects receiving any dose of CWT-001 was further compared to the mean percent change in VAS score for subjects receiving alternative treatments for lateral epicondylitis in a separate study (Figure 17E; Reference 25). This study found that corticosteroids, platelet-rich plasma (PRP), and xylocaine were all safe and effective in treating lateral epicondylitis. The percent change in VAS observed with treatment with CWT-001 in this study exceeded the percent change in VAS observed with each of the known treatments at all time points.
[0281] Efficacy assessment - ASES-E score The ASES score was developed by the Society of the American Shoulder and Elbow Surgeons to assess shoulder and elbow function (26). The ASES-E score is self-administered and has 17 questions covering symptom and function domains. Pain severity was graded on a 10-cm visual analog scale ranging from 0 (no pain) to 10 (the worst possible pain). The recall period refers to how the subject feels at this point. This validated tool was chosen because it combines subject-reported outcomes with physician assessment of changes in elbow range of motion and strength (27).
[0282] Efficacy Assessment - Quick Disability of the Arm, Shoulder, and Hand (DASH) Score The Quick DASH is an abbreviated form of the DASH, a subject-reported outcome tool developed by the American Academy of Orthopedic Surgeons in conjunction with the Institute for Work & Health (Toronto, Ontario, Canada). The Quick DASH index is self-administered and uses 11 items to measure physical function and symptoms in subjects with one or more upper extremity musculoskeletal disorders. This validated outcome measure (Reference 21) provides core information on change in a subject's function after CWT-001 injection.
[0283] Each item in the QuickDASH has five response options: 1 = no difficulty; 2 = some difficulty; 3 = moderate difficulty; 4 = very difficult; 5 = unable to do.
[0284] The results are shown in Figure 18. Reductions in QuickDASH scores were observed in subjects receiving 200 μg (Figure 18A), 500 μg (Figure 18B), or 1500 μg (Figure 18C) doses of CWT-001. At 90 days, the reduction in QuickDASH scores was greater for subjects receiving CWT-001 than for subjects receiving placebo saline injections for each dose cohort. The mean change in QuickDASH scores for all subjects receiving any dose of CWT-001 was determined and compared with placebo (Figure 18D). Treatment with CWT-001 resulted in changes in QuickDASH scores that exceeded those observed with placebo at all time points. The mean change in QuickDASH scores for subjects receiving any dose of CWT-001 also exceeded the established MCID of -20 points for DASH in patients with upper limb musculoskeletal disorders (Reference 28). The mean improvement in QuickDASH score at day 90 compared to the pre-dose score for subjects receiving the CWT-001 dose was -53±5 points.
[0285] Efficacy evaluation - Patient Rated Tennis Elbow Evaluation (PRTEE) The PRTEE, formerly known as the Patient-Rated Forearm Evaluation Questionnaire, is a 15-item self-report questionnaire for measuring perceived pain and disability in people with tennis elbow. It has three subscales: pain, usual activities, and specific activities. The pain subscale has five items regarding pain intensity during various activities. The specific activities subscale has six items reflecting difficulty experienced when performing specific activities, such as lifting a coffee cup. Four items in the "usual activities" subscale capture difficulty experienced when performing normal daily roles, including those performed at work and during recreation. The PRTEE is an excellent example of a disease-specific self-report measure. It is highly useful for capturing aspects of pain and function specific to tennis elbow rather than general joint- or region-specific measures. This validated outcome measure (Ref. 27) provides central information about changes in a subject's function after CWT-001 injection.
[0286] The results are shown in Figure 19. Reductions in PRTEE scores were observed in subjects receiving 200 μg (Figure 19A), 500 μg (Figure 19B), or 1500 μg (Figure 19C) doses of CWT-001. The reductions in PRTEE scores observed for subjects receiving the 200 μg dose of CWT-001 exceeded the reductions in PRTEE scores for subjects receiving placebo at all time points.
[0287] The mean change in PRTEE score for all subjects receiving any dose of CWT-001 was determined and compared with placebo (Figure 19D). The mean improvement in PRTEE score at day 90 was 71±6% of the baseline pre-dose score for subjects receiving either dose of CWT-001. This exceeds the MCID for clinical significance defined as "much better" or "completely recovered" for PRTEE, which is a 37% improvement from baseline (Reference 29).
[0288] Efficacy evaluation - Ultrasound evaluation The lateral tendon complex at the elbow level is easily accessible for ultrasound examination because it is located directly beneath the subcutaneous tissue and fascia. Typically, the complex is visualized as a hyperechoic linear structure aligned between corresponding attachments. Characteristic ultrasound findings of lateral elbow tendinopathy include localized hypoechoic areas within the tendon, which are associated with a loss of normal internal collagen fiber alignment. Importantly, studies have demonstrated that ultrasound features are consistent with the disease process and demonstrate resolution with symptomatic improvement using VAS and DASH scores after therapeutic treatment (Reference 30). Based on preclinical models, ultrasound assessments were performed 28 and 90 days after injection. Importantly, this provides data on the mechanism of action of CWT-001 (improvement of collagen structure) to restore normal tendon structure after treatment, which is beneficial for subject recovery and durability of treatment.
[0289] An imaging modality called ultrasound tissue characterization (UTC) can be used to visualize tendon structure and quantify tendon matrix integrity (Ref. 31). Unlike two-dimensional ultrasound and color Doppler, UTC objectively quantifies grayscale tendon matrix variations into four distinct echotypes related to tendon integrity. Type I (green) and Type II (blue) represent organized matrix; Type III (red) and Type IV (black) represent disorganized matrix (Figure 20A). The advantage of this tool compared to conventional ultrasound is that it acquires three-dimensional ultrasound images of the tendon and uses standardized parameters (transducer tilt, depth, and gain settings). Bilateral scans (on both sides of the elbow) were performed by a single examiner with experience performing UTC scans. Images were acquired using a 7-10 MHz linear ultrasound transducer (SmartProbe 12L5-V, Terason 2000+; Teratech; Burlington, MD, USA) placed in a tracking device (UTC Tracker, UTC Imaging, Stein, The Netherlands), which automatically moved a distance of 5 cm along the long axis of the tendon, recording periodic images at 0.2 mm intervals. The tilt, angle, gain, focus, and depth of the transducer were standardized by the tracking device. Images from sagittal, coronal, and transverse planes were compiled to create a three-dimensional view of the tendon. Ultrasound tissue characterization was performed before treatment (within 4 weeks) and at 28 and 90 days.
[0290] Representative ultrasound images of the lateral elbow are provided for a subject receiving placebo before injection (FIG. 20B), on day 28 (FIG. 20C), and on day 90 (FIG. 20D), and for a subject receiving 200 μg of CWT-001 before injection (FIG. 20E), on day 20 (FIG. 20F), and on day 90 (FIG. 20G).
[0291] The percentages of UTC type I, II, III, and IV tendon tissue, as well as the total percentage of repaired tendons (UTC types I and II) versus degenerated tendons (UTC types III and IV), were quantified for each subject. For each dose cohort, the percentage of repaired tendon tissue, particularly intact UTC type I tendons, increased from days 0 to 28 and 90 in subjects receiving CWT-001 and was significantly higher in subjects receiving CWT-001 than in subjects receiving placebo. There was a corresponding decrease in degenerated tendons, particularly the most severely damaged UTC type IV tendons, throughout the study period and compared with the placebo group (see Figures 20H and 20I for 200 μg CWT-001, 20J and 20K for 1500 μg CWT-001, and 20L and 20M for 1500 μg CWT-001).
[0292] The mean percentage of repaired tendon in all subjects receiving any dose of CWT-001 significantly increased from day 0 to day 28 (P<0.05) and day 90 (P<0.01); no significant change was observed in subjects receiving placebo. Subjects receiving CWT-001 also had significantly higher levels of repaired tendon at day 28 (P<0.05) and day 90 (P<0.01) and significantly lower levels of degenerated tendon at day 28 (P<0.05) and day 90 (P<0.01) than subjects receiving placebo.
[0293] Thus, the UTC data demonstrate quantifiable improvements in tendon structure in human subjects with lateral epicondylitis after treatment with a single 200 μg, 500 μg, or 1500 μg dose of CWT-001.
[0294] Example 8 - Dupuytren's Disease (Figures 15 and 16) qPCR analysis of miR29a expression in healthy and Dupuytren's fascia tissues was performed (four samples in the healthy group and three samples in the Dupuytren's group). Results showed that miR29a levels were significantly reduced in samples from Dupuytren's tissue compared to healthy controls who underwent carpal tunnel release surgery (Figure 15). These experiments demonstrated that the fibrous growth observed in Dupuytren's disease is associated with reduced miR29a expression. This observation indicated that miR-29 replacement therapy may prevent or reduce the collagen overproduction seen in Dupuytren's disease.
[0295] To further investigate whether miR-29 replacement therapy may be useful in treating Dupuytren's disease, cultured Dupuytren's fibroblasts were treated with 5 μM miR-29a mimic, miR-29b mimic, miR-29c mimic, CWT-001, miR-29a antagomir, or scrambled miR-29a control. The expression levels of collagen 1 and collagen 3 after treatment were analyzed by qPCR.
[0296] The results showed that the expression of both collagen 1 (FIG. 16A) and collagen 3 (FIG. 16B) was significantly reduced after treatment with miR-29a mimics, miR-29b mimics, miR-29c mimics, or CWT-001 relative to treatment with scrambled miR-29 control. These data indicate that treatment with miR-29 mimics, such as CWT-001, may be effective in treating Dupuytren's disease.
[0297] Example 9 - Peyronie's Disease CWT-001 will be administered to subjects with Peyronie's disease as a single intralesional (intrapenile) injection into the tunica albuginea of the penis. Subjects will be men with early-stage (acute or active) Peyronie's disease (based on the Kelami classification, Reference 32) with a penile curvature of 30° or less and / or palpable plaques less than 2 cm in area. Subjects will be followed for one year after injection. Efficacy assessments will include penile curvature, penile duplex Doppler ultrasound, pain VAS, IEFF questionnaire, and PDQ questionnaire.
[0298] It will be understood that the invention has been described by way of example only and modifications may be made which remain within the scope and spirit of the invention.
[0299] References [1]Millar et al.(2015)Nature Communication.6:6674 [2] WO2015 / 107340 [3]Watts et al.(2017)Mol Ther.25(10):2415-2426 [4]Maurer et al.(2010)Arthritis Rheum.62(6):1733-43 [5]Fabbri et al.(2012)PNAS 109(31)E2110-E2116 [6]Menzel et al.(1979)Hand 11,243-248 [7]Tubiana et al.(1968)Surgical Clinics of North America,48(5):979-984 [8]Castiglione et al.(2019)Sex Med.Mar;7(1):94-103 [9]Ralph et al.(1997)J Urol Jan;157(1):291-294
[10] Somers et al. (1989) J Urol141, 629-631
[11] Nagraba et al.(2013)Ortop Traumatol Rehabil.15(2):109-116
[12] Lake et al.(2008)Disabil Rehabil 30:1530-1541
[13] Lindow et al.(2012)Nat Biotechnol.30(10):920-3
[14] Robbins et al.(2009)Oligonucleotides19:89-102
[15] Sorani&Campbell(2016)Br J Radiol.89(1057);20150368
[16] Hjermstad et al.(2011)J Pain Symptom Manage.41(6):1073-1093
[17] Acosta-Olivo et al.(2020)Am J Sport Med.48(12):3094-3102
[18] Previtali et al.(2020)Cartilage 18:1-12
[19] Wolf et al.(2011)J Hand Surg Am 36(8):1269-72
[20] Gazendam et al.(2021)Brit J Sport Med.55:256-261
[21] Bar-Or et al.(2017)Open Rheumatol J.31;11:16-22
[22] Gao et al.(2019)Athroscopy.35(6):1847-1859
[23] Boesen et al.(2017)Am J Sports Med.45(9):2034-2043
[24] Reddy et al.(2016)J Trauma Treat 5:304
[25] Richards et al.(1994)J Shoulder Elbow Surg.3(6):347-352
[26] Longo et al. (2008) Br Med Bull.87:131-161
[27] Franchignoni et al.(2014) J Orthop Sport Phys.44(1):30-9
[28] Poltawski et al.(2011)Hand Therapy.16(3):52-57
[29] Clarke et al.(2010)Am J Sports Med.38(6):1209-1214
[30] van Schie et al.(2010) Br J Sports Med.44(16):1153-1159
[31] Kelami(1983) Urol Int.38(4):229-233
Claims
1. (a) a guide strand comprising the nucleobase sequence 5'-UAGCACCAUCUGAAAUCGGUUA-3' (SEQ ID NO:1), or a nucleobase sequence that differs from SEQ ID NO:1 at no more than three positions outside the sequence 5'-AGCACCA-3' (SEQ ID NO:8), wherein at least 50% of the nucleosides contain 2'-fluororibose and one or two nucleosides at the 3' terminus each contain 2'-O-methylribose; (b) a passenger strand comprising the nucleobase sequence 5'-ACUGAUUUCUUUUGGUGUUCAG-3' (SEQ ID NO:2) or 5'-ACUGAUUUCUUUUGGUGUUCA-3' (SEQ ID NO:3), or a nucleobase sequence which differs from SEQ ID NO:2 in no more than three positions, wherein at least ten consecutive nucleosides are alternating 2'-O-methyl ribose nucleosides and nucleosides having an unmodified ribose moiety; or a salt thereof.
2. The miR-29 compound or salt thereof of claim 1, wherein one or two nucleosides at the 3' end of the guide strand each contain a 2'-O-methyl ribose and: (i) each remaining nucleoside of the guide strand that contains a 2'-modified ribose is a 2'-fluoro ribose nucleoside, or (ii) each remaining nucleoside of the guide strand is a 2'-fluoro ribose nucleoside or an unmodified ribose moiety.
3. 2. The miR-29 compound or salt thereof of claim 1, wherein (i) each nucleoside of the guide strand comprises a 2'-modified ribose, (ii) each nucleoside of the guide strand comprises a 2'-O-methyl ribose or a 2'-fluoro ribose, or (iii) one or two nucleosides at the 3' end of the guide strand each comprise a 2'-O-methyl ribose and the remaining nucleosides of the guide strand are each 2'-fluoro ribose nucleosides.
4. The miR-29 compound or salt of any one of claims 1 to 3, wherein all of the internucleoside linkages of the guide strand and / or the passenger strand are phosphodiester internucleoside linkages. (i) the nucleobase sequence of the guide strand is as defined in SEQ ID NO:1, and / or the nucleobase sequence of the passenger strand is as defined in SEQ ID NO:2 or SEQ ID NO:3, and / or 5. The miR-29 compound or salt of any one of claims 1 to 4, wherein the guide strand is 5'-fUfAfGfCfAfCfAfUfCfUfGfAfAfAfCfGfGfUmUmA-3' and / or the passenger is 5'-mArCmUrGmArUmUmUmCrUmUrUmUrGmGrUmGrUmUrCdA-3'.
6. The miR-29 compound or salt of any one of claims 1 to 5, further comprising a cholesterol moiety covalently attached to the 3' end of the passenger strand.
7. A pharmaceutical composition comprising the miR-29 compound or a salt thereof according to any one of claims 1 to 6, and a pharma- ceutically acceptable carrier or diluent.
8. A miR-29 compound or salt according to any one of claims 1 to 6, or a pharmaceutical composition according to claim 7, for use in therapy.
9. A miR-29 compound or salt according to any one of claims 1 to 6, or a pharmaceutical composition according to claim 7, for use in the treatment of tendon injury or tissue fibrosis.
10. A miR-29 compound or salt according to any one of claims 1 to 6, or a pharmaceutical composition according to claim 7, for use in the treatment of tendon injuries, Peyronie's disease, or Dupuytren's disease.
11. 1. A miR-29 compound or a salt thereof for use in treating a tendon injury in a subject, said treatment comprising a single administration by injection of a dose of at least 47 μg of said miR-29 compound, or an equivalent dose of a salt thereof, into an injured tendon of said subject, optionally wherein said tendon injury is tendinopathy.
12. 1. A miR-29 compound or a salt thereof for use in the treatment of Peyronie's disease in a subject, said treatment comprising administration by injection of a single dose of at least 47 μg of said miR-29 compound, or an equivalent dose of a salt thereof, into the affected area of the tunica albuginea of said subject.
13. 1. A miR-29 compound or a salt thereof for use in the treatment of Dupuytren's disease in a subject, said treatment comprising administration by injection of a single dose of at least 47 μg of said miR-29 compound, or an equivalent dose of a salt thereof, into the affected area of the palmar fascia of said subject. (i) the dose of the miR-29 compound is at least 95 μg, at least 190 μg, at least 475 μg, at least 1420 μg, at least 1900 μg, at least 4270 μg, or an equivalent dose of a salt thereof; (ii) the dose of the miR-29 compound is 4740 μg or less, or an equivalent dose of a salt thereof; and / or (iii) The miR-29 compound or a salt thereof for use according to any one of claims 11 to 13, wherein said miR-29 compound or a salt thereof is administered in a volume of about 1 ml of a sterile aqueous solution. (i) the compound or salt thereof is as defined in any one of claims 1 to 6, and / or 15. The miR-29 compound or salt thereof for use according to any one of claims 11 to 14, wherein the guide strand of said miR-29 compound or salt thereof is 5'-fUfAfGfCfAfCfAfUfCfUfGfAfAfUfCfGfGfUmUmA-3' and the passenger strand of said miR-29 compound or salt thereof is 5'-mArCmUrGmArUmUmUmCrUmUrUmUrGmGrUmGrUmUrCdA-3' and comprises a cholesterol moiety covalently attached to the 3' end of the passenger strand, and wherein the dose of said miR-29 compound including the weight of said cholesterol moiety is between 50μg and 5000μg, such as 200μg, 500μg, 1500μg or 4500μg, or an equivalent dose of a salt thereof.
